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ABSTRACT Indeterminate thyroid cytology (Bethesda III and IV) corresponds to follicular-patterned benign and malignant lesions, which
are particularly diﬃcult to diﬀerentiate on cytology alone. As ~25% of these nodules harbor malignancy, diagnostic hemithyroidectomy is
still custom. However, advanced preoperative diagnostics are rapidly evolving.
This review provides an overview of additional molecular and imaging diagnostics for indeterminate thyroid nodules in a preoperative
clinical setting, including considerations regarding cost-eﬀectiveness, availability, and feasibility of combining techniques. Addressed
diagnostics include gene mutation analysis, microRNA, immunocytochemistry, ultrasonography, elastosonography, computed tomography,
sestamibi scintigraphy, [18F]-2-ﬂuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and diﬀusion-weighted magnetic
resonance imaging.
The best rule-out tests for malignancy were the Aﬁrma® gene expression classiﬁer and FDG-PET. The most accurate rule-in test was sole
BRAF mutation analysis. No diagnostic had both near-perfect sensitivity and speciﬁcity, and estimated cost-eﬀectiveness. Molecular
techniques are rapidly advancing. However, given the currently available techniques, a multimodality stepwise approach likely oﬀers the
most accurate diagnosis, sequentially applying one sensitive rule-out test and one speciﬁc rule-in test. Geographical variations in cytology
(e.g.,Hu¨rthle cell neoplasms) and tumor genetics strongly inﬂuence local test performance and clinical utility. Multidisciplinary collaboration
and implementation studies can aid the local decision for one or more eligible diagnostics. (Endocrine Reviews 39: 154 – 191, 2018)
I ndeterminate thyroid cytology is an eyesore tophysicians. It largely corresponds to histopatho-
logically follicular-patterned lesions, both benign and
malignant, including follicular adenoma (FA), non-
invasive follicular thyroid neoplasm with papillary-like
nuclear features (NIFTP), (encapsulated) follicular
variant of papillary thyroid carcinoma (FVPTC or
EFVPTC), and follicular thyroid carcinoma (FTC).
These neoplasms are particularly diﬃcult to diﬀer-
entiate on ﬁne needle aspiration cytology (FNAC). In
the case of FTC, cytology lacks the insight into the
tissue structure like histology does: it does not show
the capsular and/or vascular invasion that distin-
guishes an FTC from a benign FA. In FVPTC, the
growth pattern is follicular and clearly identifying
nuclear features of PTC can usually not be identiﬁed
cytologically (–). Nevertheless, FNAC currently has
a most prominent place in the diagnostic workup of
thyroid nodules. The Bethesda System for the
Reporting of Thyroid Cytology was adopted in its
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current form in , recognizing six diagnostic cat-
egories with an incremental risk of malignancy
and clinical management guidelines. Although the
Bethesda system created a much-used handhold by
standardizing the cytological diagnosis and consecu-
tive management of thyroid nodules worldwide, the
system does not provide a clear answer for the het-
erogeneous group of nodules with indeterminate cy-
tology (, ). This includes cytology with atypia of
undetermined signiﬁcance or follicular lesion of un-
determined signiﬁcance (AUS/FLUS, Bethesda III),
and cytology (suspicious for a) follicular neoplasm
(SFN/FN) or (suspicious for a) Hu¨rthle cell neoplasm
(SHCN/HCN, Bethesda IV). Similar indeterminate
cytological categories are found in the British Thyroid
Association Thy system and classiﬁcation of the
Societa` Italiana di Anatomia Patologica e Cit-
opatologia Diagnostica/International Academy of
Pathology, Italian Division (SIAPEC-IAP): Thya and
Thyf, and TIRA and TIRB, respectively (Table )
(, ).
Alongside a doubled incidence of thyroid carci-
noma over the past two decades and a prevalence of
thyroid nodules stretching far beyond the % for
palpable nodules, explained by the incidental detection
of nonpalpable nodules and clinically occult thyroid
cancers on imaging studies, the need for a more ac-
curate diagnostic procedure has grown (). This urge
was further emphasized when other research groups
were unable to reproduce the prevalence of the cy-
tological categories and corresponding malignancy
risks proposed by Cibas et al. (), especially those of the
AUS category (, , ). Insuperable variations in the
worldwide patient populations, and intra- and in-
terobserver variation in the assessment of thyroid
cytology, were named as likely underlying causes (, ,
, ). Yet, it raised questions concerning the overall
approach of thyroid nodule diagnosis and whether
cytology is the best starting ground. Cost-eﬀectiveness
is a major beneﬁt of cytological examination, yet
a more accurate test may eventually replace cytological
examination completely (, ). At present, however,
a supplemental diagnostic procedure is speciﬁcally
warranted for cytologically indeterminate thyroid
nodules. Diagnostic hemithyroidectomies are still
customarily performed to obtain a deﬁnite histological
diagnosis. With a benign histopathological result in
approximately three in four cases, surgery was not only
unbeneﬁcial but also exposed the patient to un-
necessary surgical risks. In the case of malignant le-
sions, a second-stage completion thyroidectomy is
often indicated, which is associated with additional
costs and higher risks of surgical complications
(–). An additional preoperative test or combi-
nation of tests for thyroid nodules with indeterminate
cytology should prevent unbeneﬁcial diagnostic
hemithyroidectomies for benign nodules, limit the
number of two-stage surgeries for thyroid malig-
nancies, or both. With rapidly advancing technology,
the possibilities for additional diagnostic techniques
seem endless: the applications of existing diagnostics
such as ultrasound (US), positron emission tomog-
raphy (PET)/computed tomography (CT), and im-
munocytochemistry (ICC) are extended and more
clearly demarcated for use in indeterminate thyroid
nodules. High-tech molecular tests such as gene
mutation panels, gene or microRNA expression
proﬁles, and sequencing techniques are hot-topic (,
–). Every currently known engagement point
from the genotype to the phenotype of the tumor is
being explored. Combined, the various research ﬁelds
encompass an extensive range of investigative
methods. Individually they usually focus on one or two
methods only, making one-to-one comparison of
these diagnostics diﬃcult. The American Thyroid
Association (ATA) guidelines suggested several ad-
ditional tests, but a deﬁnitive answer or complete
overview of all available tests is still lacking ().
Alongside higher-level expert discussions and lob-
bying of med tech companies, clinical endocrinologists
ESSENTIAL POINTS
· Indeterminate thyroid cytology (Bethesda category III and IV) corresponds to follicular-patterned benign and malignant
lesions, which are diﬃcult to diﬀerentiate on cytology alone
· Approximately 25% of indeterminate thyroid nodules harbor malignancy· The value of additional diagnostics is best deﬁned by end points such as desired minimal rates of accurately prevented
unbeneﬁcial surgeries (rule-out capacity) or accurately diagnosed carcinomas (rule-in capacity)
· None of the diagnostic techniques currently available has near-perfect sensitivity, near-perfect speciﬁcity, and cost-
eﬀectiveness
· A multimodal stepwise approach using a sensitive rule-out and speciﬁc rule-in test might oﬀer the most conclusive
diagnosis for indeterminate thyroid nodules
· The decision favoring or opposing a certain diagnostic technique strongly depends on population-dependent variations in
cytology (e.g., Hu¨rthle cell cytology), tumor genetics and prevalence of malignancy, and on the costs and feasibility of the
desired diagnostic in the local patient population
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and thyroid surgeons ponder about the best solution
for their individual patients. Their choices depend
on the characteristics of their patient populations,
availability and costs of a certain test, and personal
preference. In any case, a useful additional test should
be accurate, accessible, aﬀordable, and aﬀect patient
management.
This review aims to provide practical consider-
ations for physicians involved in the management of
patients with thyroid nodules. It gives an overview of
the available literature on additional diagnostic tests
for thyroid nodules with indeterminate cytology. We
will work our way down from genotype to phenotype,
discussing both anatomical and functional techniques,
from the state-of-the-art molecular and imaging
biomarkers, as well as widely available conventional
imaging techniques. The ability of a test to distinguish
between malignant and benign nodules in a pre-
operative setting is discussed, focusing on clinical
validation and utility, and including the development
phase, cost-eﬀectiveness, and availability of each
technique, where appropriate. Table  provides
a summarized overview of the discussed diagnostics
and their main attributes.
Molecular Biomarkers
Gene mutation analysis and gene expression
In the last decades, researchers have unraveled
important molecular mechanisms behind the thy-
roid tumorigenesis, and designated a great number
of genetic alterations that are related to the various
types of thyroid carcinoma. Several of these mu-
tational markers have found their way to the pre-
operative diagnosis of indeterminate thyroid
nodules. The most common markers are the so-
matic BRAF and RAS point mutations, and
RET/PTC rearrangement, all of which involve the
mitogen-activated protein kinase (MAPK) signaling
pathway (–).
In the  ATA guidelines, the potentially strong
diagnostic impact of molecular testing is explicitly
unfolded, focusing on BRAF testing and the, at that
date, two main commercially available tests: the seven-
gene mutation panel miRInform® thyroid (Asuragen,
Inc., Austin, TX) and the Aﬁrma® gene expression
classiﬁer (GEC) (Veracyte, Inc., South San Francisco,
CA). The ATA recommends considerate application
of one of these molecular tests for Bethesda III and IV
nodules, provided that the result could change the
treatment strategy ().
Table 1. Overview of Classiﬁcation Systems for Thyroid Cytology
Bethesda System for the Reporting
of Thyroid Cytology (4)
British Thyroid
Association (BTA) (6) SIAPEC-IAP (Italy) (7)
Malignancy
Rate (4)
Proposed Management
[2015 ATA Guidelines (8)]
Category Description Category Description Category Description
I Nondiagnostic/unsatisfactory Thy1 Nondiagnostic TIR1 Nondiagnostic 1%–4% Repeat FNAC with
US guidance
Thy1c Nondiagnostic
cystic lesion
TIR1c Nondiagnostic-cystic
II Benign Thy2 Nonneoplastic TIR2 Nonmalignant/benign 0%–3% No clinical follow-up or
treatment required
Thy2c Nonneoplastic
cystic lesion
III Atypia of undetermined
signiﬁcance/follicular
lesion of undetermined
signiﬁcance (AUS/FLUS)
Thy3a Atypical features
present
TIR3a Low-risk indeterminate
lesion
~5%–15% Repeat FNAC. If second
Bethesda III result,
consider additional tests
and/or diagnostic
hemithyroidectomy
IV Follicular neoplasm/suspicious
of a follicular neoplasm,
including Hu¨rthle cell
(oncocytic) type
Thy3f Suspicious of follicular
neoplasm
TIR3b High-risk indeterminate
lesion
15%–30% Consider additional tests
and/or diagnostic
hemithyroidectomy
V Suspicious of malignancy Thy4 Suspicious of
malignancy
TIR4 Suspicious of
malignancy
60%–75% Thyroid surgery recommended.
Consider preoperative
additional (molecular)
testing to determine
extent of surgery
VI Malignant Thy5 Malignant TIR5 Malignant 97%–99% Thyroid surgery recommended
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In the following chapters, the diagnostic potential
of mutation analysis in indeterminate thyroid nodules
is discussed, including the tests mentioned in the
guidelines, as well as other individual molecular
biomarkers and multigene panels addressed in
literature.
BRAF mutation
B-type RAF kinase (BRAF) is a serine–threonine ki-
nase belonging to the rapidly accelerated ﬁbrosarcoma
(RAF) family, and the most potent MAPK pathway
activator. Point mutations in the BRAF proto-
oncogene occur in various human cancers. The so-
matic BRAFVE mutation is the most common
activating mutation in many carcinomas, including
thyroid carcinoma (). This missense mutation
consists of a thymine-to-adenine substitution at nu-
cleotide  (c.T.A), resulting in an amino acid
substitution where valine is replaced with glutamate at
codon  (hence VE) (, ). BRAF has an
important function in cell proliferation, diﬀerentia-
tion, and apoptosis. Upregulation of BRAF through
the BRAFVE activating mutation is associated with
tumorigenesis (). In diﬀerentiated thyroid cancer,
the BRAFVE mutation is exclusive to PTC, occur-
ring in % to % of these tumors (, , ,
–, , , ). The BRAFVE mutation has
been prognostically associated with poor clinico-
pathological outcomes, such as increased incidence of
extrathyroidal invasion, recurrence of disease, and
distant metastasis of the tumor (, , ).
BRAF mutation analysis has been extensively
studied as a rule-in test for thyroid carcinoma. The
BRAF mutation is superior to other mutations in its
oftentimes % speciﬁcity, a positive mutation could
prevent two-stage surgery for an indeterminate thy-
roid nodule (, –, –, –, –). Even
though the BRAFmutation was found in a majority of
PTC in a number of studies, the prevalence of the
BRAF mutation in indeterminate cytology ranged
from % to % in individual studies (, , , , ,
). Reported sensitivities were therefore heteroge-
neous and generally poor, ranging from % to % (,
, , ). Other types of thyroid carcinoma occurring
in indeterminate nodules, including FTC, FVPTC, and
Hu¨rthle cell carcinoma [oncocytic variant of follicular
thyroid carcinoma (FTC-OV)], were respectively never
or infrequently BRAFmutation-positive (, , , ,
, , ). Predominated by follicular type carcinoma,
the BRAF mutation rarely occurs in Bethesda IV
cytology (, , , , , , , , , , , , ,
, –, , –).
Likely contributors to the observed heterogeneity
are known global variations in the occurrence rates of
PTC and BRAF mutations. In South Korea, where
iodine consumption is high, % to % of thyroid
cancers are PTC. More speciﬁcally, the proportion of
BRAF-mutated PTC is very high: rates of % to more
than % are reported (, , ). Consequently,
BRAFVE mutation analysis might have both high
speciﬁcity and high sensitivity in these populations.
Studies with higher sensitivities were more often of
South Korean origin and frequently demonstrated
sensitivity above %, with the prevalence of BRAF
mutations reported as high as % to % (, , ,
, , –). Conversely, the majority of studies with
sensitivity below % were conducted in Western
countries (United States, Europe, or Canada), with
some studies reporting no BRAF mutations at all (,
–, , , , , , –, , , , , ).
Some South Korean studies based surgical
decision-making on the result of the BRAF mutation
analysis: surgery was relatively less often performed in
BRAF mutation-negative indeterminate nodules (,
, , ). Such a surgical management strategy is not
oncologically safe for Western countries (e.g., Europa
or Northern America), where % to % of thy-
roid carcinomas are PTC and reported rates of
BRAF-mutated PTC vary from % to % (, ,
). Moreover, even though the true sensitivity of
BRAF mutation analysis is presumably high in
South Korea for the mentioned epidemiological
reasons, the conservative management of BRAF
mutation-negative nodules likely magniﬁed test
sensitivity by underestimating the rate of BRAF-
negative malignant nodules in these studies. Alto-
gether we estimate that approximately one in ﬁve
South Korean patients would beneﬁt from BRAF
mutation analysis, opposite mere one in  patients
from other countries.
BRAF mutation in papillary microcarcinoma
Papillary microcarcinoma (mPTC) have lower BRAF
mutation rates (, , , , , , ). The ATA
guidelines are reserved with regard to the recom-
mended clinical management of positive BRAF mu-
tation in mPTC, as its relation to extrathyroidal spread
and positive lymph node metastases is not as clear as in
larger thyroid carcinoma. Although there are studies
that associate mPTC to factors of poorer prognosis, the
 guidelines recommend that BRAF-mutated
mPTC are treated as low-risk malignancies (, ).
BRAFK601E point mutation
A less common activating BRAF mutation is
BRAFKE (c.A.G), which occurs considerably
less frequently than the BRAFVE variant and is
associated with FVPTC with high speciﬁcity ().
Clinically, the characterization of a small cohort of
thyroid malignancies with a BRAFKE mutation
showed better outcomes than for BRAFVE mutated
tumors: no extrathyroidal tumor extension, recurrence,
lymph node, or distant metastasis were reported in
indeterminate BRAFKE positive tumors with a me-
dian follow-up of  months (range,  to ) ().
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Table 2. Overview of Test Performance and Utility of Main Additional Diagnostics in Indeterminate Thyroid Nodules
Sensitivity Speciﬁcity Main Advantages Main Limitations Cost-Eﬀectiveness
Molecular biomarkers
Gene mutation analysis
and gene expression
BRAF 0%–83% (24–27) 99%–100%
(22, 25–67)
Perfect speciﬁcity
at low cost
Strong geographical variation in
occurrence, clinical utility likely
limited to gene mutation panels in
countries other than South Korea
Presumed, though
unpublished; V7.50 to
$123 per test (47, 55, 63,
68)
RAS 0%–77% (53, 69) 75%–100%
(53, 69, 70)
High prevalence,
frequently
detected
Often found in follicular adenomas
(false-positive); clinical utility
limited to gene mutation panels
Unpublished
RET/PTC 0%–29% (30, 43) 73%–100% (28, 30) Speciﬁc for PTC Low prevalence; clinical utility limited
to gene mutation panels
Unpublished
PAX8/PPARg 0%–29%
(25, 49, 71)
96%–100% (25, 33,
61)
No signiﬁcant
advantages
Low prevalence; utility limited to
gene mutation panels
Unpublished
7-gene mutation panel 18%–69% (23, 26) 86%–99% (26, 33) Comparatively
inexpensive
mutation panel
Speciﬁcity often insuﬃcient for
surgical decision-making
United States: likely (72);
Europe: unlikely (15);
$425 to $1700 per
test (72, 73)
NGS 71%–91% (22, 62) 89%–93% (62, 74) Highly accurate;
rapidly advancing
technology
Limited availability outside the
United States; limited
clinical validation studies
Unpublished; V230 to
$3200 per test (75, 76)
Aﬁrma® GEC 83%–100%
(77–80)
10%–52% (77, 81) High rule-out
capacity
Limited availability outside the
United States; limited high-
quality clinical validation studies
Unlikely (15, 73, 82–85);
$3500 ($1750 to $7000)
per test (73, 78, 82)
MicroRNA 57%–100%
(23, 86, 87)
58%–100% (87, 88) Stable expression
irrespective of
preservation
medium (87, 89)
Limited clinical validation,
research ongoing
Unpublished
ICC
Galectin-3 0%–92% (25, 27,
38–68, 70–166)
68%–100%
(38, 167–169)
Global availability;
inexpensive.
Limited current application in
cytology; no methodological
consensus; limited validation
studies for combinations of
immunostains.
Unpublished. Up to
V20 per test.
HBME-1 61%–100% (166,
168, 170, 171)
75%–96% (166, 168,
170, 171)
CK-19 76%–88% (166,
170, 172)
80%–100%
(166, 170, 172)
Conventional imaging
Ultrasound Dependent on
(combination
of) feature(s)
Dependent on
(combination of)
feature(s)
Global availability,
low cost
Operator dependency; limited
prospective clinical validation;
diagnostic accuracy of individual
US features insuﬃcient for surgical
decision-making
Presumed, though
unpublished.
Elastosonography 47%–97% (20,
173)
6%–100%
(174–176)
Global availability,
low cost, easily
performed during
standard US
workup
Operator dependency; limited clinical
utility studies; alternative elasticity
cut-oﬀ possibly more useful
Presumed, though
unpublished.
CT Unavailable Unavailable Unavailable Not investigated in indeterminate
thyroid nodules
NA
(Continued )
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Availability, cost-eﬀectiveness, and limitations of
BRAF mutation analysis
Altogether, the consistent perfect speciﬁcity in a large
number of studies supports the use of BRAFmutation
analysis in obviating two-stage surgery. The technique
is increasingly available in the clinical setting world-
wide. A prior meta-analysis of eight studies questioned
the cost-eﬀectiveness of BRAFVE mutation analysis
in indeterminate thyroid nodules based on a mere
.% mean prevalence of the mutation (). Cost-
eﬀectiveness studies concerning sole BRAF mutation
analysis in indeterminate thyroid nodules are lacking.
Regardless, cost-eﬀectiveness is generally presumed, as
average costs for testing are relatively low and de-
creasing over time. Depending on the applied mo-
lecular technique, reported costs for BRAF mutation
analysis ranged between V. and $ per tested
sample (, , , ).
Low sensitivity remains the main limitation of
BRAF mutation analysis, irrespective of the type of
indeterminate cytology. Proﬁciency of the test in
preoperative patient management depends on the
regional occurrence rate of BRAF-mutated PTC; in
South Korea, more patients will beneﬁt from BRAF
mutation analysis, and the probability and extent of
cost-eﬀectiveness are likely to increase (). In other
health care systems, such as in the United Kingdom,
cost-eﬀectiveness is likely more constrained. None-
theless, BRAF testing could still save approximately
half the surgical costs in BRAF mutation-positive
carcinoma (, ). These global variations should
be considered before local implementation of sole
BRAF mutation analysis.
RAS point mutation
Point mutations in the gene family of retrovirus-
associated DNA sequences (RAS) together consti-
tute the second most frequently occurring genetic
alteration in thyroid carcinoma. In indeterminate
thyroid nodules, they are the most common genetic
alteration, due to a strong association of RAS muta-
tions with the follicular-patterned lesions that make up
these cytological categories: FA, FTC, FVPTC, and
NIFTP (, , , , , ). Originally, two of the
three homologous RAS genes were identiﬁed as viral
genes of the oncogenic Harvey (HRAS) and Kirsten
(KRAS) murine sarcoma virus; the third, NRAS, was
ﬁrst identiﬁed in neuroblastoma cells (, ). The
genes code for guanosine triphosphate-binding RAS
proteins, which are involved in intracellular signaling
in the MAPK/extracellular signal-regulated kinase
(ERK) pathway. Mutation causes overactive RAS
signaling and could ultimately induce malignant
transition ().
RAS mutation in thyroid carcinoma has been as-
sociated with favorable prognostic factors, such as
encapsulation of the tumor and absence of lymph
node metastases, but also with factors indicative of an
adverse prognosis, such as poor cell diﬀerentiation ().
RAS mutations are not speciﬁc for carcinoma and
found in both malignant and benign lesions (, ,
). According to the  ATA guidelines, Bethesda
III or IV nodules with a RAS mutation should be
treated similar to the Bethesda V category, as ap-
proximately four out of ﬁve are malignant (, ).
HRAS, KRAS, and NRAS mutations are mutually
exclusive. They are each associated with slightly dif-
ferent types of cytology and histology, and conse-
quently a diﬀerent clinical course. In general, point
mutations in NRAS codon  and HRAS codon  are
said to occur most frequently (, ). KRAS is asso-
ciated with oncocytic lesions and a lower malignancy
rate than other RAS mutations ().
A RAS point mutation is found in % to % of the
indeterminate nodules (, ). Moreover, approxi-
mately one-third of all reported malignancies resulting
from indeterminate thyroid cytology are RAS muta-
tion positive, frequently FVPTC or FTC (, , , ,
Table 2. Continued
Sensitivity Speciﬁcity Main Advantages Main Limitations Cost-Eﬀectiveness
Functional and molecular
imaging
99mTc-MIBI scintigraphy 56%–79%
(20, 177)
52%–96% (20, 61) More widely
available and
lower cost
than PET
Limited test performance; limited
clinical validation studies; exposure
to limited dose of ionizing radiation
Unclear. United States
$669–$1156, Europe:
V119-V500 per scan
(84, 178, 179)
FDG-PET 77%–100%
(180, 181–184)
33%–64% (182, 185) High rule-out
capacity;
increasing global
availability
Exposure to limited dose of
ionizing radiation.
United States:
unpublished.
Europe: likely (15).
DW-MRI Unpublished Unpublished No ionizing
radiation
Limited evidence; no methodological
consensus; research ongoing
Unpublished
Abbreviations: BRAF, BRAF point mutation analysis; NA, not applicable; RAS, RAS point mutation analysis.
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). Sporadic cases of RASmutation-positive FTC-OV
and MTC are reported (, ). In individual studies,
sensitivity and speciﬁcity of RAS mutation analysis
ranged from % to % and from % to %, re-
spectively (, , ). Test performance was similar
for Bethesda III and IV categories, although the
mutation occurred more frequently in Bethesda IV
nodules (, , , , , , , , , ). His-
topathologically benign nodules carrying a RAS mu-
tation are histopathological FA in most cases, but also
oncocytic variant of FA (Hu¨rthle cell adenoma) or
hyperplastic nodules (, , , , ). There is an
ongoing discussion regarding the interpretation of
a false-positive RAS mutation. It is presumed that an
oncogenic RAS mutation predisposes a FA for pro-
gression into follicular carcinoma, an RAS-mutated FA
should be considered a premalignant preinvasive
follicular neoplasm. These assumptions put false-
positives in a diﬀerent light, as it would justify re-
section of such lesions through hemithyroidectomy.
Consequently, the lesions could also be considered
true-positives, improving the speciﬁcity of RAS mu-
tation analysis (, , , , , ). However, the
exact mechanisms behind the malignant potential and
transition for RAS-mutated follicular adenomas are
not yet clariﬁed and diﬃcult to appreciate in a clinical
setting.
Similar to BRAF, there was evident global variation
in the distribution of RAS mutations. Many European
and American studies reported a clear predominance
of RAS mutations over BRAF mutations. Solely
a Brazilian study of  Bethesda III and  Bethesda
IV thyroid nodules reported only BRAFmutations and
not a single RAS mutation (). The previously de-
scribed predominance of BRAF mutations in South
Korean populations was conﬁrmed in the sole study
that investigated both point mutations in one pop-
ulation (). Combined BRAF/RAS mutation analysis
could be considered, although geographical diﬀerences
in the distribution of the two genetic alterations
strongly inﬂuence feasibility. A gene mutation panel
consisting of more genetic alterations (discussed in
a next chapter) is most likely more useful.
Sole RAS mutation analysis is not accurate in the
preoperative setting. Although speciﬁcity is high, only
two out of three RAS mutation positive indeterminate
nodules are histopathologically malignant, evidently
fewer than assumed and previously described in the
ATA guidelines. Therefore, RAS mutation positive
indeterminate thyroid nodules should be surgically
managed with no more than hemithyroidectomy.
Whether hemithyroidectomy is justiﬁed for RAS-
mutated follicular adenomas as a precancerous lesion
is yet under debate.
RET/PTC rearrangement
Rearrangements of the RET proto-oncogene arise
from the fusion of the 9 end of RET to the 9 regions
of unrelated genes that are expressed in thyroid fol-
licular cells. Proto-oncogene RET encodes for
a transmembrane receptor with a tyrosine kinase
domain; a RET/PTC rearrangement causes in-
appropriate overexpression of that domain. It activates
the MAPK and PIK/AKT pathways and stimulates
malignant transition of the cell through BRAF (,
). At least  diﬀerent fusion variants have been
detected until today, of which RET/PTC and RET/
PTC are the most common. They have a well-known
association with PTC. Cases of both rearrangements in
a single lesion are also reported (, , , ). RET/
PTC rearrangements, especially RET/PTC, occur
more frequently in PTC in children or patients who
were exposed to ionizing radiation and are clinically
associated with the presence of lymph node metastases
(). Worldwide variations in frequency of RET/PTC
rearrangements exist, dependent on demographics
and ethnicity. The RET/PTC rearrangement is present
in % of PTC in Western populations with a pre-
dominance of RET/PTC, and in % of PTC in Asian
populations with a predominance of RET/PTC.
Without radiation exposure, in female PTC pa-
tients, RET/PTC is predominant (). The rear-
rangements are also found in benign nodules,
especially in patients who were exposed to ionizing
irradiation (, ). Alike RAS mutations, it is as-
sumed to be an activating genetic alteration and it is
argued that a histopathologically benign nodule with
an RET/PTC rearrangement should be considered
a precancerous lesion.
RET/PTC rearrangements are seldom found in
indeterminate nodules. In many studies, no RET/PTC
translocation was found at all. Most studies in-
vestigated RET/PTC in light of a gene mutation panel
and paid it no speciﬁc attention (, , , , , ,
, , , , , , , , , , ). Only Guerra
et al. () solely investigated the RET/PTC rear-
rangement in  thyroid nodules of all cytological
categories. In this Italian study, RET/PTC rear-
rangements were found in  of the  PTC (%)
using reverse transcription polymerase chain reaction
(RT-PCR) and Southern-Blot. All these RET/PTC-
positive carcinomas were Thy or Thy nodules on
cytology. Among the  Thy nodules, two nodules
with an RET/PTC rearrangement were histopatho-
logically benign ().
Noteworthy, Sapio et al. () detected two RET
mutations during their RET/PTC assessments. In
contrast to the RET/PTC translocation, RET point
mutations are related to sporadic and familial MTC
(, ). Surgery conﬁrmed histopathological MTC
in the RET-mutated nodules ().
Even though previous histological studies un-
deniably associated RET/PTC and RET/PTC rear-
rangements to PTC, the low prevalence of the
rearrangement in indeterminate cytology is a major
downside. Testing exclusively for this genetic alteration
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in indeterminate nodules is not advantageous, even if
issues regarding the number of tested variants and
sensitivity of molecular techniques are overcome. The
 ATA guidelines only advise RET/PTC testing in
context of a gene mutation panel ().
PAX8/PPARg rearrangement
The PAX/PPARg rearrangement arises from a fusion
of the promoter and 9-coding portion of the thyroid-
speciﬁc transcription factor PAX gene to the gene of
the nuclear receptor peroxisome proliferator-activated
receptor g (PPARg) (, ). The role of the
product of this translocation, the PAX/PPARg fusion
protein, is not yet understood, as the DNA binding
sites of both original proteins are uniquely preserved in
the fusion (). In the normal thyroid, transcription
factor PAX is involved in diﬀerentiation of thyrocytes
and regulation of the expression of thyroid-speciﬁc
genes encoding thyroperoxidase, thyroglobulin, and
the sodium/iodide symporter (). Nuclear receptor
PPARg has multiple presumed functions, including
involvement in the regulation of lipid metabolism,
adipogenesis, and insulin sensitivity (, ).
The chromosomal translocation PAX/PPARg
was ﬁrst discovered in, and traditionally associated
with, FTC and FA (). It is reported in % to % of
FTC and in up to % of FA (, –). However,
several studies have also uncovered varying amounts
of FVPTC carrying the translocation, with published
rates up to % (, , ). It has not been re-
ported in benign or malignant Hu¨rthle cell neoplasms
(, ).
PAX/PPARg is often related to well-diﬀerentiated
malignancies with a relatively favorable prognosis.
Capsular and vascular invasion are reported to a lesser
extent in FTCs with a PAX/PPARg rearrangement
than in RAS-mutated tumors (). Widely invasive
features are not reported. PAX/PPARg-mutated
FVPTC are mostly encapsulated, following an indolent
clinical course with minimal disease recurrence despite
the presence of some capsular and vascular invasion at
presentation (–). In contrast to the BRAF, RAS
and RET/PTC genetic alterations in thyroid carci-
noma, the PAX/PPARg rearrangement does not
involve the RAS-RAF-MAPK pathway. Nikiforova
et al. () hypothesized that oncogenesis of follicular-
type tumors likely takes place through two diﬀerent
molecular pathways: a RAS-mutation driven and
PAX/PPARg rearrangement driven pathway ().
Similar to the RET/PTC rearrangement, the PAX/
PPARg rearrangement rarely occurred in in-
determinate thyroid cytology. Approximately two-
thirds of the indeterminate nodules carrying the
rearrangement were histopathologically malignant,
most often FVPTC or FTC (, , , , , , ,
, , , , , ). False-positive results corre-
sponded to follicular adenomas (, , ). Simi-
lar to RAS mutations, histopathologically benign
PAX/PPARg-mutated nodules are likely premalig-
nant lesions, or preinvasive FTC. Eszlinger et al. ()
observed a microfollicular morphological growth
pattern in two of the PAX/PPARg-positive FA,
supporting this hypothesis ().
Still, PAX/PPARg rearrangement is a rare rear-
rangement associated with (encapsulated) follicular
tumors. Similar to RET/PTC rearrangements, the
PAX/PPARg rearrangement should only be assessed
in indeterminate thyroid nodules in combination with
more frequently occurring genetic alterations in a gene
mutation panel.
Other genetic alterations
Human telomerase reverse transcription
The enzyme human telomerase is involved in the
maintenance of the chromosomes’ telomeres, which
are essential for cell life and proliferation. The catalytic
subunit of telomerase is human telomerase reverse
transcription (hTERT). In normal thyroid cells, it is
inactive. Inappropriate reactivation is associated with
malignancy and inﬂammatory thyroid disease ().
hTERT promotor mutations were previously observed
in both PTC and FTC, sometimes together with
a BRAF mutation. The mutation is strongly correlated
to mortality in diﬀerentiated thyroid carcinoma ().
hTERT gene expression is potentially accurate in the
preoperative diﬀerentiation of indeterminate nodules,
with % to % sensitivity and % to % speciﬁcity
demonstrated in two small clinical series of cytological
follicular neoplasms (, ).
Tyrosine receptor kinase
The tyrosine receptor kinase (TRK) rearrangement
arises from a translocation of the NTRK gene, which
is normally expressed in the central and peripheral
nervous system and involved in cell diﬀerentiation.
The TRK rearrangement is associated with PTC and
presumably with an adverse prognosis, although ev-
idence is limited (). In feasibility studies in in-
determinate thyroid cytology, not a single TRK
rearrangement has been detected; it is most likely not
a useful marker (, , ).
HMGA2
Proteins high mobility group AT-hook (HMGA) 
and  regulate the structure and function of chro-
matin. Normally only expressed during embryo-
genesis, the overexpression of HMGA in adult
tissues is associated with malignancy (). Lap-
pinga et al. () demonstrated that HMGA could
be a promising additional biomarker. Using receiver
operating characteristic (ROC) curve analysis,
a ..-fold HMGA overexpression had % sen-
sitivity and % speciﬁcity in SFN/FN nodules ().
To date no other studies attempted to validate these
results.
“PAX8/PPARg is often related
to well-diﬀerentiated
malignancies with a relatively
favorable prognosis.”
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Galectin-3 and CD44v6
One Croatian study used RT-PCR to investigate the
simultaneous expression of galectin- and CDv,
two molecular biomarkers better known for their
application in immunohistochemistry (IHC) of their
expression products (). CDv normally func-
tions as the cell-surface receptor for hyaluronic acid.
Overexpression is found in various human cancers,
including thyroid (, ). In indeterminate thyroid
nodules, a positive test for either one of the two
biomarkers resulted in % sensitivity and %
speciﬁcity. It is presumed that similar results for these
markers are achieved with the more economical IHC
techniques (, ).
Gene mutation panel
Ongoing research in the past years has demonstrated
that assessment of individual oncogenic mutations
generally has limited clinical utility in indeterminate
thyroid cytology. Combining forces of individual ge-
netic alterations into a gene mutation panel, however,
likely improves diagnostic accuracy, especially as
mutations are mutually exclusive in most cases. These
gene mutation panels typically assess the seven genetic
alterations, gene mutations as well as gene fusions, that
occur most frequently in diﬀerentiated thyroid car-
cinoma, including BRAFVE, BRAFKE, NRAS
codon , HRAS codon , and KRAS codon -
point mutations and RET/PTC, RET/PTC, and
PAX/PPARg gene rearrangements (, ). The
best-known panel is the commercially available
miRInform® thyroid (Asuragen, Inc.), currently
rebranded as the ThyGenX® Thyroid Oncogene
Panel (Interpace Diagnostics, Parsippany, NJ). The
miRInform® thyroid tests speciﬁc genetic alterations
in these seven genes (). It is marketed as a rule-in test
for thyroid malignancy.
The ﬁrst large clinical utility study to investigate the
miRInform® thyroid test was published in .
Nikiforov et al. () prospectively included 
FNAC samples, % of which had suﬃcient epithelial
cells and nucleic acids to pursue molecular testing.
Residual FNAC material was used for mutation
analysis; no additional aspirates were required. Un-
fortunately, surgery was performed for only  of 
(%) indeterminate thyroid nodules, independent of
the test outcome; these operated cases were included in
their ﬁnal analysis. It is not reported whether non-
surgically managed nodules were mutation-positive or
-negative. Sensitivity and speciﬁcity were % and %
in the  Bethesda III nodules, and % and % in
the  Bethesda IV nodules, respectively. The authors
suggested that the high positive predictive value
(PPV) of the miRInform® thyroid in these in-
determinate thyroid nodules (% and %, re-
spectively) warrants a direct total thyroidectomy
instead of two-step surgery in patients with a positive
test ().
None of the subsequent studies matched the ini-
tially reported excellent speciﬁcity. The next industry-
sponsored prospective study by Beaudenon-Huibregtse
et al. () reported % sensitivity and % speciﬁcity
in  Bethesda III and IV nodules. Surprisingly, not
a single BRAF mutation was detected (). Valder-
rabano et al. () reported not a single mutation in 
included Bethesda III nodules. Moreover, only  of 
nodules with Hu¨rthle cell cytology in this study tested
positive, suggesting that Hu¨rthle cell nodules may
carry diﬀerent mutations than the ones investigated
by the miRInform® thyroid (). Ohori et al. ()
demonstrated that genetic alterations less frequently
occurred in the textbook colloid-poor Bethesda IV
cytology compared with the less common colloid-
rich variant. Diﬀerences in etiology are unknown, but
the authors hypothesized that the two types have
subtle histopathological diﬀerences. The colloid-rich
thyroid carcinomas likely more often develop
through the well-known mutations included in
the miRInform® thyroid test, whereas mutations
that elicit colloid-poor thyroid carcinoma are yet
unknown ().
Simultaneously with the American miRInform®
studies, ﬁve European studies independently in-
vestigated whether a panel of the same seven genes
could reliably be assessed using diﬀerent methods (,
, , , ). In three separate studies, Eszlinger et al.
(, , ) demonstrated that testing was also feasible
on routine air-dried FNAC samples from in-
determinate thyroid nodules. Over the course of these
studies, sensitivity of this method improved from %
to % and speciﬁcity from % to %, respectively.
The use of air-dried FNAC samples for mutation
analysis could advance the implementation of muta-
tion analysis in daily practice, as speciﬁc storage
conditions of fresh FNAC samples for mutation
analysis are no longer required (, , ). Mancini
et al. () showed that high-resolution melting (HRM)
analysis is an accurate screening method for the seven
genetic alterations, with % sensitivity and %
speciﬁcity. HRM is a post-PCR procedure that does
not require substantial additional resources. This
could reserve the costlier direct sequencing procedures
solely for samples with abnormal HRM results,
thereby reducing the overall costs of mutation analysis
().
Overall, reported sensitivities and speciﬁcities of
a seven-gene mutation panel in indeterminate thyroid
nodules ranges from % to % and % to %,
respectively (, , ). It is an adequate diagnostic
tool with a high rule-in capacity in indeterminate
nodules. Test performance was similar in Bethesda III
and Bethesda IV nodules, although the latter more
frequently had a positive test result based on the higher
prevalence of RAS mutations (, ). Due to the
common RAS mutations, PPV of the seven-gene
mutation panel never exceeds % in a range of
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realistic % to % prevalence of malignancy. As such
it is debatable whether a positive test warrants im-
mediate single-stage total thyroidectomy. It translates
into an inappropriate overtreatment in a substantial
number of patients with a positive test but benign ﬁnal
histology at higher risk of surgical complications and
all requiring lifelong levothyroxine supplementation.
Deliberate surgical decision-making should consider
the underlying positive mutation rather than merely
the positive test itself.
The limited size of the seven-gene gene mutation
panel keeps the costs per test low compared with other,
larger molecular panels. Reported prices of the seven-
gene mutation panel all concern the commercial
miRInform® thyroid (or ThyGenX® Thyroid Onco-
gene Panel) and range between $ and $ (,
). Implementation of miRInform® testing for in-
determinate nodules theoretically resulted in a %
cost reduction in the United States: the prevented two-
step surgical procedures would outweigh the added
expenses for miRInform® testing and increased
number of total thyroidectomies, including those for
nodules with a false-positive test (). In a European
setting, treatment and hospitalization costs are gen-
erally lower and miRInform® would most likely not be
cost-eﬀective (). However, these cost-eﬀectiveness
studies both adopted the unequalled test performance
from the initial key publication, true cost-eﬀectiveness
may be less optimistic (, , , ).
Next generation sequencing
To improve the sensitivity of the miRInform® thyroid
test, the existing seven-gene mutation panel was ex-
panded to include additional gene mutations, fusions,
and translocations, and a microRNA gene expression
panel. In addition, it adopted promising next gener-
ation sequencing (NGS) techniques. NGS enables the
simultaneous targeted testing for multiple mutations
in large gene panels and is faster, more sensitive, and
more cost-eﬀective than traditional Sanger sequencing
and other PCR-based methods (, , ). As NGS
only requires a very small amount ( to  ng) of
nucleic acids, remainder material from regular FNAC
passes suﬃces and no additional aspirates are required
(, ). The ﬁrst thyroid-speciﬁc NGS-based gene
panel was the ThyroSeq® v (CBLpath, Ocala, FL),
presented in . It detected gene variations in  of
 investigated thyroid cancer tissue samples and  of
 benign specimens. Unfortunately, indeterminate
FNAC samples were not analyzed separately in this
study. Nonetheless, Nikiforova et al. () demon-
strated that NGS had a very high success rate and
could be a promising molecular technique for thyroid
FNAC samples.
Following the ThyroSeq® v, the road was paved
for further exploration of NGS-based diagnostics.
Soon, the ThyroSeq® v (CBLPath, Ocala, FL) was
developed, with a number of primers for TERT
promotor variants added to its panel. It simultaneously
tested for point mutations in  genes and for  types
of gene fusion products (). The ThyroSeq® v was
tested on  Bethesda IV thyroid nodules. Forty-two
genetic alterations were found, most frequently NRAS.
Diagnostic accuracy of the ThyroSeq® v was %,
with astonishing % sensitivity and % speciﬁcity
().
More recently, Nikiforov et al. () tested the
ThyroSeq® v., including point mutations in  genes
and  gene fusion transcripts, in  Bethesda III
nodules. Based on the promising results of the pre-
vious study, surgery was withheld for  of 
ThyroSeq®-negative patients. In the  patients with
available histopathology, the ThyroSeq® v. dem-
onstrated % sensitivity and % speciﬁcity. Addi-
tionally, diagnostic accuracy was estimated for
malignancy rates varying between % and %: PPV
would range from % to %, negative predictive
value (NPV) from % to %. Within reasonable
limits, the ThyroSeq® v. is highly reliable to rule out
malignancy ().
Le Mercier et al. () retrospectively tested a dif-
ferent commercially available -gene NGS panel, the
Ampliseq Cancer Hotspot Panel v (ThermoFisher,
San Diego, CA), which is a tumor-nonspeciﬁc NGS
panel for detection of somatic tumor variants. This
panel does not include thyroid-speciﬁc RET/PTC,
PAX/PPARg, and NTRK rearrangements. Albeit
the study only assessed  FNAC samples, with %
sensitivity and % speciﬁcity in indeterminate thyroid
nodules, the Ampliseq panel seems less accurate
than the ThyroSeq® ().
The high diagnostic accuracy is also a downside to
NGS. Highly sensitive, NGS is able to identify mutant
alleles at very low levels (,%). A low percentage of
mutant alleles might reﬂect a subclone within the
nodule, which is not histopathologically identiﬁed as
carcinoma. This detection of germline or clinically
insigniﬁcant low-level somatic mutations in benign
nodules could decrease NGS speciﬁcity (, ).
Nikiforov et al. () suggested that the next im-
provement of the NGS-related tests should therefore
be to determine accurate threshold levels for the
various gene variations ().
NGS encompasses crucial technology that is rap-
idly advancing. The ThyroSeq® v was recently an-
nounced, promoting to encompass no less than ~%
of genetic alterations occurring in PTC. Extraordinary
diagnostic accuracy above % is anticipated, in-
cluding high accuracy in Hu¨rthle cell lesions. Results of
the prospective studies validating this new version will
likely be published shortly. Nonetheless, NGS tech-
niques currently have limited global availability, with
the exception of some European countries and the
United States. The ThyroSeq® is available for $
per test (). In contrast, the thyroid nonspe-
ciﬁc AmpliSeq panel can be ordered online for only
“Deliberate surgical decision-
making should consider the
underlying positive mutation
rather thanmerely the positive
test itself.”
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V (). Independent prospective studies are needed
to validate its performance and predicted cost-utility in
diﬀerent patient populations, and conﬁrm the superior
position of the ThyroSeq® and other NGS techniques.
Aﬁrma® GEC
In molecular diagnostics, the chief competitor of the
seven-gene mutation panel is the commercial Aﬁrma®
GEC (Veracyte, Inc.). The GEC uses quantiﬁcation of
the messenger RNA (mRNA)-expression of  genes
and a proprietary classiﬁcation algorithm to determine
the probabilities of malignancy in the samples’ ex-
pression patterns. The classiﬁcation algorithm to
discern a “benign” (negative test) from a “suspicious”
(positive test) thyroid nodule results from a successful
designer study that trained the GEC in both a tissue set
and diverse FNAC sample sets with known histopa-
thology (). Alexander et al. () performed the ﬁrst
prospective, blinded, industry-sponsored clinical study
to validate this Aﬁrma® GEC in patients with in-
determinate thyroid nodules. From  hospitals 
Bethesda III, IV, and V FNAC samples were collected,
obtained by two additional needle aspirates from
thyroid nodules with a diameter of at least  cm. After
exclusion of over half (/, %) of the samples
for reasons such as nodules that were not surgically
resected, duplicate specimens from the same nodule,
and issues with specimen shipments to Veracyte, ﬁ-
nally  FNAC samples were included in the analysis.
Sensitivity of the Aﬁrma® GEC was % in the 
Bethesda III as well as the  Bethesda IV nodules with
a useful GEC-negative test result in % (/), but
speciﬁcity was merely % and %, respectively (%
on average). Despite the relatively high malignancy
rate in Bethesda III nodules and the high number of
exclusions, this study is well conducted and recognized
worldwide as the landmark study that demonstrated
the strength of the Aﬁrma® GEC (). After the
overwhelming results from this key publication,
popularity of the GEC took ﬂight. It is marketed as
a highly accurate rule-out test for malignancy in
thyroid nodules with indeterminate cytology.
In , the ﬁrst multicenter study that retro-
spectively assessed the clinical utility of the Aﬁrma®
GEC was published. Only % of reported GEC-
negative Bethesda III, IV, and V nodules eventually
underwent surgery, of which one resulted in a -mm
mPTC. Unfortunately, data on GEC negative nodules
were only reported on an aggregate level; exact test
performance rates in Bethesda III and IV nodules
cannot accurately be extracted from the publication.
Less than half of the GEC-negative nodules without
surgery (/, %) had clinical or radiological
follow-up, ranging from  to  months (median
 months), a limited duration compared with the
natural, indolent course of diﬀerentiated thyroid
carcinoma. The published paper does not describe
whether the remaining  patients with GEC-negative
nodules received any follow-up at all. Despite evident
limitations to the applied reference standards, Alex-
ander et al. () concluded that their results conﬁrm
both the accurate test performance from their prior
study, as well as the large impact that the Aﬁrma® GEC
has on clinical decision-making for cytologically in-
determinate thyroid nodules.
Yet, physicians indeed seemed reassured by
a negative GEC result based on the ﬁrst studies alone
(, ). In many institutions in the United States, the
Aﬁrma® GEC was immediately implemented in
clinical practice. The retrospective studies that fol-
lowed were mere postimplementation utility studies,
and generally reported very high but moderately
consistent sensitivities. GEC-negative nodules were
largely managed without surgery and considered true-
negative, resulting in possible overestimation of test
sensitivity. Long-term follow-up is not yet available to
endorse a benign diagnosis in these cases (, ).
The high degree of missing histology was recognized
by most of these studies as a major limitation (, ,
, –). This was conﬁrmed by the  ATA
guidelines: recognizing the Aﬁrma® GEC as a prom-
ising diagnostic tool, the guidelines stress that it is
a major shortcoming that external clinical validation
studies with full histological follow-up of Aﬁrma®
GEC-negative nodules are still lacking ().
Not all studies were able to conﬁrm the potential of
the Aﬁrma® GEC. Some struggled with a low benign
call rate (i.e., useful negative test result that could lead
to management change) (, ). McIver et al. ()
questioned the cost-eﬀectiveness of the Aﬁrma® GEC
in their population, as the mere % (/) negative
test rate was much lower than anticipated. Moreover,
one-quarter of these GEC-negative patients rejected
the proposed conservative treatment of US-based
follow-up and underwent surgery anyway; one of
them was diagnosed with a .-cm FTC with focal
capsular and vascular invasion. Also, % of GEC-
positive nodules proved histopathologically benign,
overall resulting in a disappointing % sensitivity and
% speciﬁcity ().
Besides concerns regarding adequate clinical vali-
dation of test performance, the postimplementation
inﬂuence of the GEC on surgical decision-making for
individual patients was also questioned. In line with
the results of their preliminary study, Noureldine et al.
() demonstrated that Aﬁrma® GEC testing had not
aided surgical decision-making (, ). In %
(/) of the included indeterminate nodules,
a “benign” or “suspicious” GEC result did not aﬀect
management at all: the surgical strategy would have
been identical had it been based merely on clinical,
cytological, or radiological suspicion. However, if
management changes were based on the GEC result,
they were more often wrong than right:  times GEC-
positive results inappropriately tempted physicians
into more aggressive surgery, and total thyroidectomy
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was performed instead of the initially recommended
lobectomy for nodules that proved histopathologically
benign. In contrast, in just four GEC-positive cases the
more aggressive surgery was appropriate and the
nodule was histopathologically malignant. Also, in just
one patient surgery was withheld speciﬁcally due to
a negative Aﬁrma® GEC result. In the other unresected
GEC-negative nodules, surgery was not clinically in-
dicated to begin with; the negative GEC-result merely
endorsed conservative management (). As the GEC
was still a new technology when this study was
conducted, it is possible that the involved physicians
were unsure of the correct interpretation of the GEC
results or hesitant to rely on a negative GEC result.
However, clinical suspicions and physician and patient
preference will always be considered when making
surgical decisions.
Yang et al. () elegantly tried to solve the
shortcoming (histological) follow-up by comparing
their ﬁndings of GEC performance to a pre-GEC
cohort of similar patients from their hospital in all
of whom surgery was performed (, ). The reported
malignancy rates were comparable pre- and post-GEC
implementation (% vs %), and obviously relatively
more surgeries were performed for benign nodules in
the pre-GEC period. Assuming the true malignancy
rates in the successively studied populations are in-
deed similar, the GEC only modestly reduced the
number of futile surgeries for benign thyroid nodules
from % to % (). Altogether, the contribution
of the Aﬁrma® GEC to the surgical decision-making
may be more limited than expected based on its
diagnostic accuracy.
Availability, cost-eﬀectiveness, and limitations of
the GEC
The Aﬁrma® GEC is currently only available for
routine use in the United States. There are high de-
mands for the FNAC specimens regarding sample
preservation and shipping. Cytology is revised by
Veracyte cytologists and declined if not strictly
Bethesda III or IV, with % to % discordancy
between local assessment and central review, com-
parable to known interobserver rates for thyroid cy-
tology (, , ). Reported rates of nondiagnostic
GEC test results due to insuﬃcient quantity or quality
of the mRNA are substantial, varying from % to %
(, ). Insuﬃcient mRNA quality was often caused
by problems with long duration of the sample ship-
ment to Veracyte (, ). Fourth, Aﬁrma® GEC
testing is expensive and is currently marketed for
$ (range $ to $) per test (, , ).
Testing for medullary carcinoma and BRAF mutation
is not included in the Aﬁrma® GEC, but can be
performed by Veracyte at additional costs (). Yet,
ancillary BRAF mutation testing may not be relevant,
as Kloos et al. () found that it improved sensitivity
nor speciﬁcity of the GEC.
Studies of cost-eﬀectiveness yielded variable results,
but most concluded that GEC testing would not be
cost-eﬀective over conventional surgical management
or other diagnostic modalities in various clinical set-
tings (, , –). The ﬁrst of these studies pro-
claimed cost-eﬀectiveness of the GEC even prior to
publication of the ﬁrst validation study by Alexander
et al. (), and has been criticized for several important
methodological caveats. This study professedly over-
estimated test speciﬁcity at %, overestimated the rate
of permanent complications from thyroid surgery, and
did not consider the regularly reported GEC test
failures (–, , , , ). A recent study de-
termined population-dependent thresholds for feasi-
ble cost-eﬀectiveness by comparing GEC performance
to conventional surgical management in a local
Bethesda III/IV population. GEC-guided management
was not cost-eﬀective, adding $ to the $,
expenses for conventional treatment while hardly
improving quality-adjusted life years. Sensitivity
analysis showed that the GEC would only become
cost-eﬀective if its speciﬁcity exceeds %, if it costs
less than $, or if the population malignancy rate
decreases from the actual % to below .%. This
price threshold for cost-eﬀectiveness decreases as the
malignancy rate increases, as low as $ per test at
% cancer prevalence ().
Furthermore, existing interinstitutional diﬀerences
in test performance have consequences for local ap-
plicability and eﬀectiveness (, ). Marti et al. ()
compared GEC performance in distinct populations of
two large hospitals. The reproducibility of the tests’
sensitivity and speciﬁcity was good, but utility strongly
depended on the local prevalence of malignancy: as the
population malignancy rate increased, a rarer negative
GEC became less reliable to rule out malignancy.
Oppositely, at low malignancy rates, a negative GEC
merely conﬁrmed that the probability of cancer was
low. In neither situation, the GEC changed the
management strategy. GEC testing was most useful if
the malignancy rate ranged between % and %,
comparable to the prevalence reported by Alexander
et al. (, ).
Finally, the degree of missing histology is a major
limitation to the performed studies. None of the
studies following the key publication by Alexander
et al. () had complete histopathologic follow-up;
histopathological conﬁrmation ranged between %
and % of specimens.
Missing histology mainly comprised GEC negative
nodules, likely resulting in overestimated sensitivity
(i.e., missing some malignancies in the many unop-
erated GEC-negative nodules) and underestimated
speciﬁcity [i.e., relatively more GEC-positive nodules
with benign histology (false-positives) were operated
on than GEC-negative nodules with benign histology
(true-negatives)]. The trend that studies with higher
surgical rates for GEC-negative nodules showed more
“GEC testing was most useful if
the malignancy rate ranged
between 15% and 21%,
comparable to the prevalence
reported by Alexander et al.”
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moderate results supports these hypotheses (, ,
).
A recent meta-analysis by Santhanam et al. ()
included seven studies and reported % pooled
sensitivity and % pooled speciﬁcity for the GEC in
Bethesda III, IV, and V thyroid nodules with histo-
pathological follow-up. The authors expected that
more than % of patients with a negative test would
be treated conservatively (). However, in individual
studies up to % of patients pursued surgery or
conservative treatment despite GEC-based recom-
mendation to do the opposite (, ). This obser-
vation is crucial to cost-utility analyses. In addition,
expensive rule-out tests such as the Aﬁrma® GEC
should not be performed in case surgery is considered
for other reasons, such as cosmetic or mechanical
complaints.
GEC in Hu¨rthle cell cytology
Brauner et al. () speciﬁcally validated the Aﬁrma®
GEC in  cytology samples suspicious for Hu¨rthle
cell neoplasm. They demonstrated that GEC testing
could accurately have reduced the number of futile
surgeries, although through a less profound re-
duction than in nononcocytic indeterminate thyroid
nodules (). Similar results were noticed in other
studies: despite a relatively low risk of malignancy, the
majority of Hu¨rthle cell nodules were GEC-positive.
Regardless of good sensitivity, this unfavorable be-
nign call rate in Hu¨rthle cell cytology limits di-
agnostic eﬃcacy in these nodules, increasing the
number needed to test and negatively aﬀecting
possible cost-eﬀectiveness (, , , , , ).
Diagnostic accuracy of the GEC would likely improve
if Bethesda IV cytology suspicious for a Hu¨rthle cell
lesion was excluded from GEC testing. Otherwise,
similar to the additional testing for medullary car-
cinoma, adaptations should be made to the Aﬁrma®
GEC to improve its clinical utility for Hu¨rthle cell
lesions.
In conclusion, it is generally assumed that the
Aﬁrma® GEC accurately reclassiﬁes approximately
two out of ﬁve indeterminate thyroid nodules as
benign with published sensitivities ranging between
% and % and similar test performance in
Bethesda III and IV nodules. Withholding diagnostic
surgery from these patients seems safe (–).
However, the diagnostic strength and potential cost-
utility of Aﬁrma® GEC strongly rely on its NPV, thus
on the prevalence of malignancy and benign call rate
in the targeted population. There are important
concerns regarding the currently insuﬃcient number
of clinical validation studies with adequate rates of
histopathological conﬁrmation or long-term clinical
follow-up. Physicians are strongly advised to locally
validate Aﬁrma® GEC test performance before
considering test implementation in daily practice.
Nonetheless, further large validation studies on the
Aﬁrma® GEC may soon become obsolete, as an
updated version of the test, the Gene Sequencing
Classiﬁer (Veracyte, Inc.), is currently being put into
operation. Improved diagnostic accuracy is antici-
pated, with speciﬁc attention to the diﬀerentiation of
Hu¨rthle cell nodules.
MicroRNA
First described in thyroid cytology in , evaluation
of the expression levels of microRNA (also called
miRNA) is among the newer and more promising
approaches to diﬀerentiate between benign and ma-
lignant thyroid neoplasms (, ). MicroRNAs are
small endogenous noncoding RNAs of ~ nucleo-
tides in length. As negative regulators (i.e., silencers) of
protein synthesis at a posttranscriptional level, they are
involved in many intracellular processes, including cell
growth, diﬀerentiation, and proliferation. Dysregula-
tion of microRNA expression is found in almost all
types of human cancers (). It reﬂects the deregu-
lated expression of oncogenes and tumor suppressor
genes (, , , ). MicroRNA overexpression is
present before morphological tissue changes are seen
and therefore considered to be a part of premalignant
changes in carcinogenesis (). MicroRNA expres-
sion proﬁles are tissue-speciﬁc and cannot only
identify the tissue of origin, but also the histopatho-
logical subtype of the cancer and whether it concerns
the primary tumor or a metastasis (, ).
MicroRNA expression proﬁles are similar among
the various types of thyroid carcinoma, even though
expression levels are often distinctively diﬀerent ().
In histopathological studies, PTC was associated with
an up to - to -fold upregulation of miR-b,
miR-, miR-, miR-b, miR-, and a down-
regulation of miR- and miR- compared with
healthy thyroid tissue and benign nodules. Upregu-
lation of miR-, miR-, and miR- was also
found in FTC, FTC-OV, poorly diﬀerentiated and
anaplastic carcinoma (, , , , ). Over-
expression of miR-b-p, miR-b-p, and miR-
 was seen in both PTC and FVPTC (, ).
Furthermore, expression levels of miR- and miR-
 were reported approximately twice as high in
FVPTC as compared with PTC or FTC (). Only
a few microRNAs were diﬀerently expressed between
follicular neoplasm and FTC (). FA was associated
with the expression of miR-a, whereas high ex-
pression of miR-was found in Hu¨rthle cell adenoma
(). FTC is related to the diﬀerential expression of
miR-b, miR--p, miR-, miR-, and miR-,
but results among studies are more heterogeneous (,
, ). FTC-OV showed an expression pattern
slightly similar to FTC, but also distinct overexpression
of other microRNAs, such as miR-, miR-, miR-
, and miR--p (, ).
Accordingly, a diagnostic panel of a carefully se-
lected combination of microRNAs and appropriate
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expression levels could aid in the preoperative dis-
tinction of indeterminate thyroid cytology (). Re-
cent meta-analyses struggled to reconcile the studies
on microRNA in FNAC, as the investigated set of
microRNAs was never identical and individual
microRNA performance was infrequently described.
In unselected cytology, estimated sensitivity of
microRNA expression analysis ranged from % to
% regardless of the investigated set; estimated
speciﬁcity from % to % (–).
In indeterminate thyroid cytology, diﬀerent sets of
microRNAs were evaluated; only several individual
microRNAs were analyzed in more than one study.
The selected microRNAs were ﬁrst assessed in a test set
of cytological and/or histopathological specimens and
a cut-oﬀ for their expression level was determined.
Subsequently, the signiﬁcantly up- or downregulated
microRNAs were validated in an independent set of
(indeterminate) thyroid FNAC samples. Some studies
developed a decision model for the validation step (,
, ).
The most promising results were presented by
Keutgen et al. (). Of the six microRNAs in-
vestigated in their test set, miR-, miR-b, miR-
a, and miR- were diﬀerentially expressed in
malignant nodules with prior indeterminate cytology.
The subsequently developed support vector machine
model incorporated miR-, miR-, and the in-
signiﬁcantly expressed miR- and miR-. Pro-
spective validation in an independent set of 
indeterminate FNAC samples resulted in %
sensitivity and % speciﬁcity. Five of the seven false-
positives had Hu¨rthle cell cytology; excluding these,
raised speciﬁcity to % (). Notably, even though
overexpression of miR-b is often related to thy-
roid carcinoma, it proved not useful to Keutgen et al.
() to include in their prediction model. In contrast,
Agretti et al. () and Shen et al. () included miR-
b as the key diﬀerentiators in their models. Agretti
et al. () assessed a frequently quoted set of
microRNAs consisting of miR-b, miR-, miR-
, miR-, miR-, miR-, and miR- (,
). Published in , Nikiforova et al. () had
demonstrated that this seven-microRNA set in
FNAC samples had % sensitivity and % spec-
iﬁcity if one of the included microRNAs showed an at
least twofold overexpression. Analytic validation of
this model by Agretti et al. () showed diﬀerential
upregulation in PTC of all of these microRNAs
except miR-. In particular, miR-b showed
a.-fold higher expression in PTC. A decision tree
including miR-b, miR-, and miR- was %
accurate in the test set, but validation in an in-
dependent set of indeterminate FNAC samples was
unsuccessful, yielding mere % sensitivity and %
speciﬁcity ().
Vriens et al. () used a microRNA array to detect
 genes that were up- or downregulated by at least
ﬁvefold in thyroid malignancies. Four microRNAs
(miR-, miR-b, miR-, and miR--p) were
signiﬁcantly downregulated and accurately diﬀeren-
tiated between benign and malignant follicular and
Hu¨rthle cell neoplasms in the test set. In their vali-
dation set of  indeterminate FNAC samples, only
miR- was moderately distinctive with % NPV.
For Hu¨rthle cell carcinoma, miR- and miR--p
were both % accurate ().
Finally, in a recent Italian study, only miR-
accurately diﬀerentiated between benign and malig-
nant neoplasms. Subsequently, in TIR cytology ex-
cluding Hu¨rthle cell lesions, a -fold or higher
overexpression of miR- perfectly distinguished
benign from malignant lesions with % accuracy. It
was also signiﬁcantly diﬀerently expressed between
TIRA and TIRB categories and correlated with
a diﬀerent malignancy risk ().
Availability and limitations of microRNA
expression analysis
MicroRNA expression analysis has advantages over
other techniques. MicroRNAs are more stable than
mRNA at maintaining their expression in formalin-
ﬁxed paraﬃn-embedded tissue samples as well as
FNAC specimens, irrespective of the preservation
method (e.g., archived FNAC slides or nucleic acid
preservation solutions) (, ). Recently microRNA
expression was even successfully measured in serum
(). Moreover, microRNA expression levels mea-
sured with generic methods (e.g., quantitative RT-
PCR) correspond well to their biological eﬀect, as
microRNAs aﬀect biological processes without the
additional step of protein synthesis ().
However, general limitations of FNAC also
translate to concerns with microRNA analysis: scant
cellularity or low levels of malignant cells in FNAC
specimens could cause a false-negative microRNA test
result (). Another limitation is the plurality of
microRNAs associated with diﬀerentiated thyroid
carcinoma in histopathological studies, causing vast
heterogeneity between the limited number of studies
in indeterminate cytology. Validation studies of the
same microRNA set are lacking. Simultaneously, new
microRNAs are still correlated to thyroid carcinoma.
Ongoing research has yet to compose the optimal set
of microRNAs. Recently, the ﬁrst commercial test was
marketed as the ThyraMIR (Interpace Diagnostics).
It evaluates the expression levels of miR-b-–p,
miR-–p, miR-–-p, miR-–p, miR-b-
p, miR-, miR-–p, miR-–p, miR-, and
miR-b-p. The ThyraMIR demonstrated %
sensitivity and % speciﬁcity in  Bethesda III and
IV FNAC specimens (). Prospective clinical vali-
dation of the ThyraMIR could aﬃrm the diagnostic
value of microRNA expression proﬁling in in-
determinate thyroid nodules in the preoperative
setting.
“Ongoing research has yet to
compose the optimal set of
microRNAs.”
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Immunocytochemistry
Tissue characterization through selective staining of
expressed proteins, i.e. IHC, is a technique that
combines histopathology and biochemistry. Exploiting
basic antigen–antibody interactions, IHC is able to
visualize the distribution and localization of speciﬁc
cellular components within the cell and in the proper
tissue context. This includes tissue biomarkers speciﬁc
for infection or malignancy. IHC has been fully in-
corporated in the histopathological routine and is
crucial to morphological and molecular tissue char-
acterization. When ICC, the application of this
immunology-based technique in cytology, became
available, the possibilities were extended to the pre-
operative setting, too. Speciﬁc immunomarkers have
been developed to diﬀerentiate between benign and
malignant thyroid nodules. The  ATA guidelines
acknowledge ICC as a technique under development
with limited prospective validation studies in in-
determinate cytology (). In unselected thyroid cy-
tology, the much-used immunomarkers galectin-,
Hector Battifora mesothelial- (HBME-), and cyto-
keratin  (CK-) demonstrated %, %, and %
sensitivity, and %, %, and % speciﬁcity, re-
spectively ().
Galectin-3
Galectin- is a b-galactosyl-binding protein from the
lectin group. It is involved in cell-cycle regulation,
including cell migration and adhesion. Its exact
function is still to be unraveled, but a role in the
pathogenesis and progression of PTC is presumed (,
–). It is related to inhibition of apoptosis, in-
duced by abnormal p expression (). Galectin-
can be present both in the intracellular as well as the
extracellular matrix (). Normal thyrocytes do not
express galectin-, but the physiological expression of
galectin- in macrophages, neutrophils, mast cells, and
Langerhans cells provides an internal positive control
of the investigated FNAC samples (, ). Positive
cytoplasmic staining, as opposed to nuclear staining,
for galectin- is suspicious for malignancy and mainly
associated with PTC (, , ). Galectin- ex-
pression has also been associated with the malignant
transformation of follicular neoplasms, as it was
present in FA as well as FTC (, , ). En-
capsulated FVPTC and minimally invasive FTC
showed less frequent and weaker staining (, ).
In , Bartolazzi et al. () argued that
galectin- staining could accurately diagnose thyroid
carcinoma in unselected thyroid cytology. Sub-
sequent studies in indeterminate thyroid cytology
mostly could not reproduce these promising results.
With a positive stain in approximately one-third of
all nodules, sensitivity and speciﬁcity of galectin-
ranged from % to % and from % to %,
respectively (, –). Merely Saggiorato et al.
() demonstrated that galectin- accurately
diﬀerentiated follicular adenomas from FTC with
% sensitivity and % speciﬁcity if a cytoplasmic
stain in $% of the cells was considered positive
(). The prospective multicenter clinical validation
study by Bartolazzi et al. () demonstrated %
sensitivity and % speciﬁcity in Thy nodules if
a cytoplasmic galectin- stain in.% of the cells was
considered positive. Nineteen of the  false-positive
nodules were FA. However, a group of  diﬃcult-
to-diagnose (follicular) tumor of unknown malig-
nant potential lesions was disregarded,  of which
were galectin- negative. If these neoplasms were
considered malignant, sensitivity dropped to %
().
HBME-1
HBME- is a monoclonal antibody targeting an un-
known antigen on the microvilli of mesothelial cells. It
is usually negative in normal thyroid follicular cells.
Abnormal expression of HBME- shows cytoplasmic
location with membrane accentuation. It is associated
with, but does not necessarily indicate PTC (, ,
, ). Its low detection limit enables assessment in
liquid based cytology (). Reported sensitivity and
speciﬁcity of HBME- in indeterminate nodules
ranged from % to % and from % to %,
respectively (, , , ). Approximately two
out of ﬁve nodules showed positive staining. If only
nononcocytic follicular neoplasms were selected,
Saggiorato et al. () demonstrated that HBME- had
excellent % sensitivity and % speciﬁcity in in-
determinate thyroid nodules.
Cytokeratin 19
CK- is a type I keratin. It belongs to the group of
intermediate ﬁlament proteins, which arrange the
cell cytoskeleton and structural integrity. CK- is
widely present in epithelial cells, but also found in
basal cells layers of stratiﬁed epithelium (, ).
Strong and diﬀuse abnormal expression of CK-
indicates PTC, including FVPTC. Expression in
FTC is less intense and more variable, warranting
nuanced interpretation of CK- staining intensity.
CK- usually shows no or only focal expression in
follicular neoplasms, hyperplastic nodules, and
adenomatous goiter (, , , ). The re-
ported sensitivities and speciﬁcities for CK-
staining in indeterminate cytology ranged from
% to % and % to %, respectively (, ,
). Lacoste-Collin et al. () demonstrated the
importance of an accurate threshold. CK-
staining in  Bethesda IV nodules accurately di-
agnosed ﬁve out of six malignancies, including
a PTC, two FTC, and two out of three FVPTC. At
a threshold of $% stained cells,  of  benign
lesions tested false-positive; at a more sensitive
threshold of $% stained cells,  of  tested
false-positive ().
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Other ICC markers
IHC studies identiﬁed more potential ICC markers.
Some, like CDv, have not yet been investigated in
indeterminate cytology (). Other markers were
sporadically investigated in preclinical studies, in-
cluding Ki-, TROP-, emerin, keratan sulfate, thy-
roperoxidase, CD, and GLUT-.
Nuclear protein Ki- is expressed in nearly all cell
cycle phases in proliferating cells. It is associated with
poor prognosis in PTC (). The percentage of cells
with Ki- expression is considered the tissues’ pro-
liferative index. At a cutoﬀ of $% Ki- was %
sensitive and % speciﬁc for thyroid carcinoma in
Bethesda IV nodules. A combination of HBME-, CK-
, and Ki- immunomarkers was % accurate to
diagnose malignancy (). Ki- expression is likely
only distinctive for follicular type carcinoma; ex-
pression in PTC is generally low (, , ).
Glycoprotein human trophoblast cell surface
marker (TROP-) is overexpressed on the cell surface
of diﬀerent epithelial carcinoma (e.g., breast, colon)
and associated with tumor aggressiveness and poor
prognosis. In indeterminate thyroid cytology, it was
only assessed in one small subseries of Bethesda III
samples, correctly diagnosing the three included car-
cinoma and all but one of the nine benign nodules
().
Emerin staining emphasizes features of the nu-
clear membrane often seen in PTC, such as irreg-
ularities and invaginations. Consequently, the stain
could facilitate the morphological diagnosis of PTC
and especially the more diﬃcult-to-diagnose FVPTC
(, ). In  Thy nodules assessed by Asioli
et al. (), positive emerin staining was highly
speciﬁc for PTC (including FVPTC), but mis-
diagnosed all FTCs.
Another immunomarker associated with PTC is
keratan sulfate, an abnormal glycosaminoglycan
complex. It was % speciﬁc in indeterminate cytology,
but correctly predicted PTC only; its sensitivity was
poor at % ().
The expression of thyroid peroxidase (TPO) is
related to benign follicular neoplasms. A negative TPO
stain was % sensitive and % speciﬁc for thyroid
malignancy ().
Finally, CD (Leu) expression is associated with
epithelial and nonepithelial malignancies, including
thyroid carcinoma. Cytological staining was only in-
vestigated in a small series of indeterminate cytology,
but seemed speciﬁc for PTC. In the same series,
GLUT- was not a useful ICC marker, there were no
positive stains ().
Combined use of ICC markers
Some research groups have suggested that evident
single-marker galectin- positivity is suﬃcient to
refer a patient for total thyroidectomy (, , ).
The ATA guidelines did not adopt these suggestions,
and many other researchers advocate that a panel of
ICC markers should be applied to strengthen the
suspicion of malignancy (, , , ). Several
panels were investigated in literature. Zhang et al.
() assessed a triple stain of galectin-, HBME-
and p. P is a cyclin-dependent kinase inhibitor
related to cell life span in normal thyroid cells.
Downregulated in malignancy, positive P stain is
related to benign histopathology. In a set of Bethesda
III cytology samples, positive p staining with
negative galectin- and HBME- staining was %
predictive of a benign nodule and occurred in % of
samples. Loss of p staining in combination with
positive galectin- and/or HBME- staining was
% sensitive and % speciﬁc (). Another study
investigated galectin- and HBME- in combination
with a RET proto-oncogene stain, which reﬂects
abnormal intracellular RET proto-oncogene activity
and presence of the RET/PTC rearrangement. Un-
fortunately, RET staining was inaccurate in in-
determinate thyroid nodules ().
To ﬁnd the most accurate combination of
immunostains, Saggiorato et al. () explored the
expression of galectin-, HBME-, thyroperoxidase,
CK-, and keratan-sulfate in  cytological follicular
neoplasms,  of which were Hu¨rthle cell lesions.
Galectin- was not only the most accurate marker
individually, but also in combination with other stains.
Sequential HBME- staining of galectin--negative
cases reached % sensitivity and % speciﬁcity in
nononcocytic lesions. In oncocytic lesions, sequential
CK- staining was more preferred with % sen-
sitivity and % speciﬁcity ().
The common denominator between all these
studies is the combined use of galectin- and HBME-.
Unfortunately, clinical validation studies regarding
this combination are limited. Its seemingly promising
diagnostic accuracy warrants further assessment in
future prospective studies.
Performance of ICC in Hu¨rthle cell cytology
Expression of ICC markers in Hu¨rthle cell nodules
diﬀers from nononcocytic indeterminate cytology.
Hu¨rthle cell carcinomas were distinguished in the
cytological samples by typical overexpression of
markers associated with a high degree of cell pro-
liferation, disorganized tissue structure, and in-
termediate diﬀerentiation, such as Ki-, laminin,
cyclin D, and cyclin D. Overexpression reﬂects the
known more erratic behavior of Hu¨rthle cell carci-
noma (, ). Moreover, markers that were highly
diagnostic in indeterminate nodules in general, also
seem diﬀerently expressed in Hu¨rthle cell lesions.
Saggiorato et al. () demonstrated that two com-
binations of ICC markers were extraordinarily accu-
rate: galectin- and CK- staining was % sensitive
and % speciﬁc; galectin- and thyroperoxidase
staining was % sensitive and % speciﬁc ().
“The common denominator
between all these studies is the
combined use of galectin-3
and HBME-1.”
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In a previous meta-analysis, inclusion of Hu¨rthle
cell lesions was related to between-study heterogeneity
(). Hu¨rthle cell lesions require a biotin-free ICC
method, as Hu¨rthle cells themselves are rich in biotin.
Thus, much-used biotin-based methods may conse-
quently cause false-positive and highly intensive
staining in Hu¨rthle cell neoplasms (, , ).
Availability, cost-eﬀectiveness, and limitations
of ICC
Current application of ICC is limited. Clinical vali-
dation studies for all of the described immunomarkers
are scarce, and no cost-eﬀectiveness studies are
available to date. Yet, the technique is widely available,
relatively inexpensive and fast in comparison with
other (molecular) techniques. Costs per immunostain
vary up to V, partly depending on simultaneous
local application of the technique and similar stains for
IHC.
ICC is preferably performed on cell block FNAC
specimens, but can be performed in all types of cy-
tology, from direct smears to liquid-based cytology
(, ). ICC is impossible when the FNAC spec-
imen has poor cellularity or too much obscuring blood
(). Also, immunostaining of cytology is technically
more diﬃcult than histological staining, especially in
(destained) cytology smears. Technical inconsistency
and interobserver variation likely lead to false-negative
results (, ). Stain intensity thresholds or per-
centage of stained cells necessary to raise suspicion of
malignancy vary in the available literature. Consistent
methodology and assessment thresholds should be
determined to improve reproducibility of ICC results.
Clinical validation studies of existing ICC markers
are ongoing. Meanwhile, new markers are also playing
the ﬁeld, searching for the interfaces between mutation
analysis of highly speciﬁc oncogenic driver mutations
and accessible ICC techniques. For example, Leslie
et al. () investigated ICC of the BRAFVE mutation
using the mutation speciﬁc antibody VE in a small
series of thyroid FNAC samples. Concordance be-
tween ICC and conventional BRAFVE mutation
analysis was %. All samples that were BRAFVE
positive by either method were conﬁrmed as
BRAFVE positive PTC on histopathology. Of the
eight included indeterminate thyroid nodules, seven
were histopathologically malignant and BRAFVE
mutation was detected in two nodules: one by both
methods, one only by molecular analysis. The
BRAFVE speciﬁc antibody (VE) stain was much
weaker in cytology than in histology. Moreover, costs
of the VE antibody are currently high and optimi-
zation of methodology is warranted. Yet, Leslie et al.
() demonstrated that BRAFVE mutation analysis
using ICC is a promising alternative to mutation
analysis. If future studies could validate these results in
larger cohorts of indeterminate thyroid nodules and
detect reliable immunomarkers for other oncogenic
driver mutations, this technique unites the strengths of
gene mutation analysis and ICC in one technique,
though likely at lower costs.
In general, ICC is a widely available and relatively
inexpensive technique with a reasonable diagnostic
accuracy. Many immunomarkers seem to have
a pronounced association with PTC. Galectin- and
HBME- were most frequently investigated, but their
speciﬁcities and sensitivities seem to fall short of
justifying ICC-based surgical decision making. Di-
agnostic accuracy of their combined use seems
promising, yet current evidence is limited. Prospective
validation trials are warranted to conﬁrm the di-
agnostic potential of ICC, including validation of
thresholds for stain positivity, panels of multiple
immunostains, and other methodology.
Conventional Imaging
Ultrasound
US is one of the principal steps in the initial workup of
thyroid nodules. It is cheap, fast, noninvasive, and
globally available, but accurate assessment strongly
depends on operator experience (). Multiple meta-
analyses showed that well-known US features such as
nodule hypoechogenicity, microcalciﬁcations, irregu-
lar margins (including microlobulated or ill-deﬁned
margins), and a taller-than-wide shape raise the sus-
picion for thyroid malignancy and are mostly asso-
ciated with PTC (, ). Nonetheless, no single US
feature is suﬃciently sensitive or speciﬁc to accurately
identify a malignant nodule in an unselected pop-
ulation (). Certain combinations of US features,
however, may oﬀer accurate closure. The current ATA
guidelines now include a ﬂowchart recommending
FNAC dependent on nodule size and various com-
binations of US characteristics with an incremental
risk of malignancy (). Despite the obvious importance
of both US and cytology, the ATA guidelines do not
provide recommendations regarding (re)interpreta-
tion of US characteristics after FNAC has resulted in
indeterminate cytology. Follicular-type malignancies
typically have a diﬀerent US appearance. More often
FTC may be iso- to hyperechoic, with a spherical
shape, smooth regular margins, and no calciﬁcations
(, ). FVPTC may also show FTC-like or benign
features rather than the classic suspicious features,
although microcalciﬁcations may be distinctive
(–). In the past years, Brito et al. () and
Remonti et al. () performed meta-analyses on US
assessment of unselected thyroid nodules. Both also
brieﬂy discussed its diagnostic value in indeterminate
nodules, including a mere limited number of studies
and also including cytology suspicious for malig-
nancy. Increased central vascularization was most
predictive of malignancy with reported % speci-
ﬁcity (). Yet, in general US seemed less accurate in
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indeterminate nodules than in unselected thyroid
nodules (, ).
In the dozens of available original ultrasound
studies, individual US features generally demonstrated
limited sensitivity in indeterminate thyroid nodules.
Only the appearance of a solid thyroid nodule, as
opposed to varying degrees of cystic content, had high
sensitivity. Ranging between % and %, multiple
studies demonstrated sensitivity above % (, ,
–).
A number of classic suspicious US characteristics,
such as a taller-than-wide shape, presence of irregular
margins, and presence of microcalciﬁcations, dem-
onstrated valid speciﬁcity in indeterminate thyroid
nodules. Speciﬁcities for each of these characteristics
ranged from % to % (–), % to % (,
, ), and % to %, respectively (, ).
Despite the wide range, presence of microcalciﬁcations
was more than % speciﬁc in many studies (, ,
, –, , , –). Large nodule size
(deﬁned as a diameter larger than  cm) was only
investigated in a limited number of studies. Reported
speciﬁcities ranged between % and % (, ).
Other features, such as a solitary nodule, hypo-
echogenicity and absence of a hypoechoic halo were
associated with thyroid malignancy, but less accurately
diﬀerentiated between benign and malignant in-
determinate thyroid nodules (, , , ,
–). Additionally, opposing the results from one
of the mentioned meta-analyses, central vasculariza-
tion also does not seem very accurate in indeterminate
thyroid nodules. Speciﬁcity ranged from % to %,
although multiple studies demonstrated extremely
poor speciﬁcity (, , –).
Results regarding two US features are remarkably
contradicting. First, the absence of a hypoechoic halo is
typically considered suspicious for malignancy, but
showed overall poor and very heterogeneous di-
agnostic potential in indeterminate thyroid nodules
(). Sensitivity and speciﬁcity ranged from % to
% and % to %, respectively (, , , ,
). Presence of a hypoechoic halo is typically con-
sidered a benign feature, but has also been associated
with follicular types of thyroid carcinoma ().
Dogan et al. () reported % speciﬁcity for presence
of a halo in AUS/FLUS nodules and % in FN/SFN
nodules. Second, the ultrasonographic nodule shape
seems ambiguous. Similar to the unselected pop-
ulation, a typically suspicious taller-than-wide shape
was generally speciﬁc for carcinoma, with reported
speciﬁcities up to % (, , ). A spherical
shape is generally considered benign, but has also been
associated with FTC (, , ). In two studies in
cytological follicular neoplasms, a spherical shape had
an increased risk of malignancy, with % to %
sensitivity and % to % speciﬁcity (, ). Chin
et al. () even suggested that follicular neoplasms
with a taller-than-wide shape could be treated
conservatively. The uniquely balanced rates of PTC,
FVPTC, and FTC resulting from indeterminate cy-
tology may explain why these and various other US
characteristics have diﬀerent diagnostic accuracy than
in the unselected population. Dependent on the local
case mix, accurate diﬀerentiation of indeterminate
nodules using the classical suspicious US features may
or may not be feasible.
Combination of US characteristics
A combination of US characteristics likely provides
more accurate diﬀerentiation than individual features.
Diﬀerent combinations were investigated in multiple
studies (, , , , –, , –). Yoo
et al. () reported % speciﬁcity for the combi-
nation of marked hypoechogenicity and taller-than-
wide shape, a pattern that occurred in .% (/) of
the included Bethesda III nodules. In the elastoso-
nography study by Rago et al. (), absence of
a hypoechoic halo in combination with presence of
microcalciﬁcations was % speciﬁc for thyroid ma-
lignancy, but only .% sensitive. Maia et al. ()
found % sensitivity and % speciﬁcity in Bethesda
III and IV nodules if hypoechogenicity, micro-
calciﬁcations, an irregular margin, and increased
intranodular vascularity were considered suspicious.
Gulcelik et al. () demonstrated that the US pattern
of a solid, hypoechoic nodule with microcalciﬁcations
had % sensitivity and % speciﬁcity. The pattern
was seen in % of cytological follicular neoplasms.
In multiple studies, it was argued that cytological
follicular neoplasms with a typically benign US pattern
(a regular shape, isoechoic, homogeneous, with well-
deﬁned margins, cystic components or peripheral
vascularity only, and not a single malignant feature)
could be safely followed up clinically instead of un-
dergoing diagnostic surgery (, , ). Consid-
eration of more features generally increased the
sensitivity of the US assessment at the cost of its
speciﬁcity (, ). The terms of their interpretation
were crucial: Norle´n et al. () demonstrated that US
was % sensitive and % speciﬁc if a Bethesda III
nodule had either hypoechoic appearance, irregular
margins, or microcalciﬁcations. If solely the simulta-
neous presence of all three features was considered
suspicious for malignancy, sensitivity dropped to %
but speciﬁcity increased to %.
Altogether, diagnostic US scores or step-by-step
algorithms could aid the classiﬁcation of US patterns
and consequent risk of malignancy (, , ).
Best-known and most validated is the Thyroid Im-
aging Reporting and Data System (TIRADS), a clas-
siﬁcation to risk-stratify thyroid nodules, designed by
Horvath et al. () and modiﬁed by Kwak et al. ()
following the example of the similar BIRADS classi-
ﬁcation for breast lesions. The TIRADS assigns
nodules to a risk category based on ﬁve suspicious US
features: solid appearance, (marked) hypoechogenicity,
“Altogether, diagnostic US
scores or step-by-step
algorithms could aid the
classiﬁcation of US patterns
and consequent risk of
malignancy.”
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irregular margins, microcalciﬁcations, and a taller-
than-wide shape. Nodules without any of these fea-
tures are likely benign and categorized as TIRADS .
Their risk of malignancy is ~.% in a cytologically
unselected population. TIRADS  includes suspicious
nodules, which are further classiﬁed according to an
increasing malignancy risk into a (one suspicious US
feature), b (two suspicious features), and c (three or
four suspicious features). Nodules with all ﬁve sus-
picious US features are classiﬁed as TIRADS  and
associated with a high % risk of cancer in an un-
selected population (). Studies that validated the
TIRADS speciﬁcally in indeterminate thyroid nodules
showed that diagnostic accuracy depended on the
chosen cutoﬀ score and type of cytology (, ,
–). Although TIRADS  scores were in-
frequently assigned in indeterminate nodules, a higher
TIRADS score (b/c/) was an accurate predictor of
malignancy, especially in Bethesda IV cytology (,
, ). In Bethesda III nodules, lower TIRADS
scores (/a) could also rule out malignancy (, ).
Prospective validation studies applying the TIRADS in
indeterminate cytology are warranted to assess its
possible clinical utility in indeterminate nodules.
US performance in Hu¨rthle cell nodules
Cytological Hu¨rthle cell nodules expressed a large
variation of US characteristics (, , , ).
Many malignant and most benign Hu¨rthle cell nod-
ules had a benign US appearance (, ). Only
three US features possibly predictive of malignancy
were reported in individual studies: both hypo-
echogenicity and hyperechogenicity (as opposed to
isoechogenicity) (), large nodule size (), and
microcalciﬁcations (). Despite limited evidence, US
evaluation does not seem reliable to diﬀerentiate
Hu¨rthle cell lesions.
Availability and limitations of ultrasonography
The major advantages of US over other additional
diagnostics are its already permanent position in the
workup of thyroid nodules, global availability, and low
costs. No additional resources or hospital visits are
needed to include US interpretations in preoperative
management decisions and the investigation is non-
invasive. Nonetheless, besides known limitations
concerning interobserver variability and less reliable
interpretation of small nodules, US feasibility in in-
determinate thyroid nodules is limited by the pre-
sumed diﬀerences in US appearance of papillary and
follicular thyroid malignancies, illustrated by the
conﬂicting results for nodule shape and hypoechoic
halo in indeterminate nodules. Consequently, local
diagnostic accuracy likely follows variations in the
local histopathological case mix.
In addition, many of the available ultrasound
studies are retrospective, limiting the power of the
evidence. As the decision to perform FNAC is
customarily based on the results of the prior US, the
prevalence of suspicious US features in indeterminate
cytology in these studies is presumably overestimated.
Nonetheless, several individual US characteristics
seem to have reasonable speciﬁcity in indeterminate
nodules, although insuﬃcient for accurate diagnosis. A
combination of US features is likely more accurate,
although current evidence does not support US-based
surgical decision-making. We propose that a future
meta-analysis should use the individual patient data
from the large number of available original studies to
develop a US algorithm speciﬁcally for indeterminate
thyroid nodules. The existing TIRADS needs pro-
spective validation.
Even though more advanced and less operator-
dependent techniques might be preferred, US features
should always be assessed in current clinical practice.
The presence of one or more suspicious US features in
a Bethesda III or IV nodule increases the suspicion of
malignancy and underpins the need for a deﬁnite
diagnosis. Moreover, to centers or regions with limited
access to other (molecular) diagnostics, US may def-
initely have clinical utility, pending local validation in
the indeterminate population.
Elastosonography
Firm consistency of a thyroid nodule upon palpation is
considered suspicious for malignancy, an established
principle during physical examination (). US
elastosonography (USE) is a dynamic US technique
that is sometimes referred to as “electronic palpation.”
Tissue elasticity is evaluated by measuring tissue
distortion while applying a standardized dosed ex-
ternal force by the US transducer. It was ﬁrst applied to
the thyroid gland by Lyshchik et al. () in .
Classic real-time qualitative USE is performed by free-
hand compression and a sine-wave or numerical scale
showing how much pressure the operator applies with
the probe. A color-coded elastosonography image is
superimposed on the grayscale US images: red and
orange visualizes high tissue elasticity (soft tissue),
green represents intermediate elasticity, and blue low
elasticity (ﬁrm tissue). Several score systems are
available. The original score was developed by Itoh
et al. () in  for the evaluation of breast tumors
and considers scores  to  benign on a scale of 
(highest elasticity) to  (no elasticity). Rago et al. (,
) ﬁrst applied it to thyroid tumors and modiﬁed it
to a three-point score. Asteria et al. () derived
a modiﬁed four-point score.
The earliest studies in thyroid nodules reported
opportune results of USE as an additional modality to
B-mode US, but were heterogeneous in USE technique
and study population (). A recent meta-analysis by
Nell et al. () included  studies on qualitative USE
prior to FNAC and concluded that qualitative USE is
ﬁt to diagnose benign nodules and safely dismiss
FNAC, provided that the usual elasticity score cutoﬀ is
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abandoned and only completely soft nodules (score 
of all systems) are classiﬁed as benign. Pooled %
sensitivity and % negative predictive value dem-
onstrated the ability of USE to reliably rule-out ma-
lignancy in entirely soft thyroid nodules, composing
% of their pooled study population ().
In individual studies on USE in indeterminate
nodules, sensitivity and speciﬁcity of qualitative USE
ranged from % to % and from % to %, re-
spectively (, –). Results of several qualitative
USE studies stand out. Lippolis et al. () showed an
aberrant .% speciﬁcity, because they reported only
eight nodules with high elasticity,  of  benign
nodules were not elastic. The authors themselves
suggest that a rather homogenous study population
with predominantly small nodules with a solid US
pattern, absence of cystic areas, and follicular histology
with minimal colloid could be explanatory for the poor
speciﬁcity rather than operator-dependent causes
(). Such possible relations remain undescribed in
other studies. A meta-analysis on the value of USE in
indeterminate thyroid nodules demonstrated meager
pooled % sensitivity and % speciﬁcity ().
As manually applied pressure is diﬃcult to stan-
dardize, qualitative USE is strongly operator de-
pendent (). Diﬀerent USE techniques have been
developed to improve objectivity, such as semi-
quantitative tissue-to-nodule strain ratio indices (also
based on manual compression). Studies investigating
semiquantitative USE in indeterminate thyroid nod-
ules reported sensitivity and speciﬁcity ranging from
% to % and from % to %, respectively (,
, , ). Furthermore, quantitative shear wave
USE measures the propagation velocity of focused
acoustic pulses, shear waves, from the probe, which
correlate to tissue stiﬀness (Young’s modulus) (,
). It had % sensitivity and % speciﬁcity in
a recent prospective pilot study by Samir et al. ().
Performance of (semi)quantitative USE seems better
than qualitative USE, but results are subject to over-
ﬁtting from the ROC analysis performed to determine
the strain ratio cutoﬀ value with the highest sensitivity
and speciﬁcity. None of the studies applied a pre-
deﬁned cutoﬀ or validated their own cutoﬀ externally.
Consequently, the resulting thresholds were hardly
comparable (, , , ).
Altogether, the results from currently available
studies cannot support surgical decision-making in
thyroid nodules with indeterminate cytology using
elastosonography in any of its forms. Whereas color-
coded qualitative USE has insuﬃcient sensitivity and
speciﬁcity, the semiquantitative method lacks valida-
tion. The power of the available evidence is addi-
tionally limited by both methodological heterogeneity
and the use of diﬀerent USE techniques, image pro-
cessing, and elasticity scoring methods across studies.
Nevertheless, the suggested promising rule-out ca-
pacity of qualitative USE when applying an alternative
cutoﬀ score of  in unselected nodules deserves clinical
validation in indeterminate thyroid nodules. Major
advantages of the technique are the minor extra costs
of USE, as it can be performed during regular thyroid
US with the same equipment, and only adds
~ minutes to the procedure time per patient. Cost-
eﬀectiveness will largely depend on performance of
USE, but no cost-eﬀectiveness studies in indeterminate
thyroid nodules are available to date.
Computed tomography
There are no studies that investigated CT scanning in
thyroid nodules with indeterminate cytology. Prior
studies indicated that CT cannot accurately diﬀeren-
tiate thyroid carcinoma (, ).
Functional and Molecular Imaging
99mTc-MIBI
Hexakis(-methoxy--methylpropylisonitrile)techne-
tium[mTc] (mTc-MIBI) is a Technetium-m-
labeled radiopharmaceutical, primarily known for its
use in myocardial perfusion imaging since the s
and more recently the evaluation of hyperparathy-
roidism. Uptake of mTc-MIBI, a lipophilic cation,
reﬂects both perfusion and the number of active mi-
tochondria in the cells of the thyroid nodule and thus its
oxidative burden (, ).
mTc-MIBI scintigraphy is more suitable for the
diﬀerentiation between benign and malignant thyroid
nodules than scintigraphy with mTc-pertechnetate
(mTcO
2) or radioisotopes of iodide (often
I2,I2 or I2). These latter tracers interrogate
the sodium-iodide symporter of the thyrocyte and are
frequently used to assess thyroid nodule functioning
to distinguish autonomous (“hot”) from hypo-
functioning (“cold”) nodules. They are neither spe-
ciﬁc nor eﬀective to detect malignancy: benign
nodules can be anything from hyper- to hypo-
functioning, and far outnumber the carcinomas. Still,
thyroid malignancies are almost always hypo-
functioning: decrease of the sodium-iodide sym-
porter or TPO are hallmarks of cell dediﬀerentiation
and lead to loss of iodide-trapping function and
thus mTc-pertechnetate or radioiodine uptake
(, –). mTc-MIBI uptake is independent of
iodide trapping and organiﬁcation in the thyrocytes.
Nodules with increased uptake and late retention
of mTc-MIBI are suspicious for malignancy
(, ). A  meta-analysis by Treglia et al. ()
demonstrated % sensitivity and % speciﬁcity for
mTc-MIBI scintigraphy in clinically suspicious,
hypofunctioning, cytologically unselected thyroid
nodules. Hyperfunctioning benign adenomas can
show false-positive increased uptake of mTc-MIBI
due to their increased metabolic needs, thereby de-
creasing test speciﬁcity.
“As manually applied pressure
is diﬃcult to standardize,
qualitative USE is strongly
operator dependent.”
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Only three studies investigated the role of mTc-
MIBI in indeterminate thyroid nodules. In all studies,
evaluation of thyroid nodules was performed by dual-
time planar imaging: an early image was made ranging
from  to  minutes after injection of the radio-
pharmaceutical and a delayed image  to minutes
post injection. The intensity of the mTc-MIBI uptake
within the nodule, and possible increased uptake or
denoting retention on delayed imaging were assessed
and compared with the physiological washout of the
tracer from normal thyroid tissue. A visual pattern of
increased mTc-MIBI uptake on early images that
persisted or further increased on the delayed images
was generally considered suspicious for malignancy.
The individual study sensitivity and speciﬁcity for this
interpretation ranged from % to % and from %
to %, respectively (, , ). Despite the limited
number of available studies, the performance of
mTc-MIBI in indeterminate thyroid nodules seems
insuﬃcient and less accurate than in cytologically
unselected nodules ().
Nonetheless, Giovanella et al. () demonstrated
that NPV for this method could increase from % to
% if only the pattern of mTc MIBI uptake lower
than or equal to the pertechnetate uptake within the
nodule was considered benign. As few benign lesions
expressed this uptake pattern, this would decrease the
yield of this diagnostic.
Piccardo et al. () did not preselect hypo-
functioning lesions, but included all indeterminate
thyroid nodules. As expected given the explanation
above, the speciﬁcity of mTc-MIBI was poor: %.
Assessment of a retention index of the tracer based
on semiquantitative measurements of the lesion to
nonlesion uptake ratios for early and delayed mTc-
MIBI images yielded better accuracy. Optimal
thresholds for the retention index were determined
using ROC analysis and unfortunately not externally
validated (, ). As such, it is unclear whether
semiquantitative mTc-MIBI retention indices are
truly more accurate than conventional visual assess-
ment. Moreover, semiquantitative analysis is still
operator dependent, as it depends on the manual
deﬁnition of ranges of interest (ROI) ().
99mTc-MIBI in thyroid nodules with Hu¨rthle
cell cytology
Oncocytic cells are rich in mitochondria. Therefore,
Hu¨rthle cell lesions, malignant as well as benign,
frequently show a more intense and persistent mTc-
MIBI uptake (, , ). Boi et al. () in-
vestigated mTc-MIBI in cold thyroid nodules with
varying proportions of Hu¨rthle cells in the cytology
samples. A relation between mTc-MIBI uptake and
increased tissue density of oncocytes was suggested
(). Subsequent studies also concluded that mTc-
MIBI is not speciﬁc enough to diﬀerentiate in-
determinate lesions with Hu¨rthle cell cytology (, ,
). Excluding Hu¨rthle cell nodules from mTc-
MIBI assessment likely excludes many false-positive
tests while improving benign call rate, speciﬁcity, and
overall diagnostic accuracy in indeterminate thyroid
nodules.
Availability, cost-eﬀectiveness, and limitations
of 99mTc-MIBI
Imaging of mTc-MIBI requires conventional gamma
cameras [with or without single-photon emission
computed tomography (SPECT) and CT], which are
more widely available than PET, especially in non-
Western countries. Furthermore, the tracer itself is
more widely available due to relatively simple com-
plexation using mTc-MIBI-kits together with the
favorable half-life of mTc (~ hours) obtained from
on-site generators. The radiation burden of the
recommended whole-body adult dose is  to  mil-
lisievert, but can be lowered by a factor  to  by
partial-body imaging (). However, the system
resolution of state-of-art gamma cameras is a factor
 lower than of PET/CT cameras. This decreases the
measured signal of lesions smaller than  mm, in-
creasingly limiting test sensitivity in smaller nodules.
Average costs of mTc-MIBI scanning range from
V to V in Europe and from $ to $ in
the United States (, , ). From a German
perspective, mTc-MIBI-based management was cost-
eﬀective over Aﬁrma® GEC-testing and conventional
management. However, this study inappropriately
extrapolated auspicious performance parameters of
mTc-MIBI in unselected thyroid nodules (%
sensitivity and % speciﬁcity) to the indeterminate
population, and likely underestimated modeled costs
for mTc-MIBI scanning and thyroid surgery (, ,
, , , , ). Therefore, these assumptions
regarding cost-eﬀectiveness in indeterminate thyroid
nodules are decidedly questionable and require careful
re-evaluation.
Altogether, there is an increased risk of malignancy
in thyroid nodules that show increased mTc-MIBI
uptake, provided that hypofunctioning nodules are
preselected. Nonetheless, test performance in in-
determinate thyroid nodules seems insuﬃcient. Ex-
cluding Hu¨rthle cell lesions suggests high speciﬁcity,
but does not resolve the reported poor sensitivity.
However, the number of studies currently available for
indeterminate thyroid nodules is limited. We believe
prospective validation studies in nononcocytic in-
determinate thyroid nodules should be performed.
Future studies should also focus on external
threshold validation for retention indices to reduce
operator dependency and increase accuracy and
objectivity of mTc-MIBI. Based on the current
evidence, we recommend that mTc-MIBI scanning
is not used in surgical management decisions
in indeterminate thyroid nodules without another
adjunctive test.
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[18F]-2-ﬂuoro-2-deoxy-D-glucose PET
PET using [F]--ﬂuoro--deoxy-D-glucose (ﬂuo-
rodeoxyglucose or F-FDG), also known as FDG-
PET, is an imaging modality that exploits the basic
principle that (malignant) tumors and inﬂammatory
tissues are much more metabolically active than
normal tissues. Whereas normal tissues pre-
dominantly produce energy by low rates of aerobic
glycolysis followed by the citric acid cycle in mito-
chondria, glycolytic rates of rapidly growing cancers
can be up to  times higher. Subsequent lactic acid
fermentation takes place even if oxygen is plentiful
(the Warburg eﬀect) (). Similar to regular glucose,
the glucose analog F-FDG is internalized by trans-
membranous GLUT transporters and converted by
hexokinase to F-FDG--phosphate. However, unlike
the -phosphorylation product of regular glucose, F-
FDG--phosphate cannot be metabolized further. It is
trapped intracellularly and thus accumulates in the
tissue. Subsequently, PET scanning can visualize the
increased glucose metabolism of the (abnormal) tissue
(). Nowadays, FDG-PET is generally performed in
combination with CT (FDG-PET/CT), mainly to
correlate metabolically active regions to their anatomic
substrates and to correct for tissue-attenuation of the
radioactive signal. It is increasingly applied in the
diagnostic workup, staging, and therapeutic response
monitoring of various malignancies. For thyroid
cancer, FDG-PET is frequently used to characterize
recurrent disease, especially if dediﬀerentiation is ex-
pected in thyroid carcinomas that lost the capacity to
concentrate radioiodide, yet still have measurable
serum values of the tumor marker thyroglobulin. It
may also be considered in the initial staging of poorly
diﬀerentiated or invasive Hu¨rthle cell carcinoma.
Moreover, FDG-avid thyroid incidentalomas require
additional workup by FNAC when . cm (, ). In
the current ATA guidelines FDG-PET is not routinely
recommended for the diagnostic workup of in-
determinate thyroid nodules due to limited clinical
validation, despite a meta-analysis by Vriens et al.
() that demonstrated % sensitivity and % NPV
in indeterminate thyroid nodules larger than  mm
(, ).
Results of available individual studies were mu-
tually consistent despite limited sample sizes. The ﬁrst
studies showed extremely promising results; each
reporting % sensitivity (–). De Geus-Oei
et al. () argued that implementation of FDG-PET
could reduce the number of futile hemithyroidectomies
for benign nodules by %, likely outweighing the
costs of the extra scans and suggesting cost-
eﬀectiveness of this technique in the preoperative
setting. A subsequent study suggested a less optimistic
% reduction in futile surgeries, following a lower
benign call rate (). More recent studies demon-
strated more modest performance of FDG-PET(/CT)
(, , , , ). Overall, reported sensitivity and
speciﬁcity of FDG-PET(/CT) to detect thyroid carci-
noma in indeterminate thyroid nodules ranged from
% to % and from % to %, respectively. A
negative index test was reported in ~% of patients
(, , –, , ).
Several reasons for false-negativity were proposed,
foremost small nodule size. It is how Traugott et al.
() explained their % false-negative FDG-PET
scans: eight lesions were histopathologically smaller
than  cm. Excluding these, sensitivity and NPV in-
creased to %. FDG-avidity in very small nodules
may be missed on FDG-PET due to the low volume of
malignant cells and due to the partial volume eﬀect:
the detected FDG-concentration is underestimated
dependent on nodule size in relation to the (limited)
spatial resolution of the scanner. In larger nodules, this
eﬀect is negligible (, ). Although the improving
resolution of state-of-the-art PET scanners pushes the
detection limit toward  mm, PET is less sensitive in
lesions smaller than  mm on US. It is less reliable to
rule-out microcarcinomas (). Theoretically, the
improving spatial resolution could also become
a limitation of the technique: not only will there be less
false-negatives, but likely also more false-positive re-
sults, leading to a decrease in the already limited
speciﬁcity over time. In the currently available liter-
ature, no such downward trend is noted, but future
studies should monitor this possibility.
Semiquantitative FDG-PET
Semiquantitative analysis of FDG-PET is performed
using the maximum standardized uptake value
(SUVmax): the ratio between the maximum radioac-
tivity concentration measured within a region of in-
terest on the PET image (the “hottest” voxel) and the
decay-corrected amount injected radiotracer per unit
of body mass. It reﬂects the FDG-concentration factor
compared with a homogenous distribution of the
radiotracer (). The SUVmax is generally signiﬁcantly
higher in malignant than in benign lesions (,
–, , ). There is a possible correlation
between higher SUVmax values and increasing size in
nodules, insuﬃciently explained by the above-
mentioned partial volume eﬀect (, ). Also, in
FTC a higher SUV was associated with capsular or
vascular invasion (). Nonetheless, even though
Kresnik et al. () demonstrated that all carcinoma
and Hu¨rthle cell adenoma had aSUVmax $  and all
other benign lesions a SUVmax , , in multiple other
studies the SUVmax of benign and malignant in-
determinate thyroid nodules overlapped. No threshold
could accurately tell them apart (, –, ,
). Moreover, as SUVmax calculations strongly de-
pend on image acquisition and reconstruction
methods, type of PET-scanner, and other variable
methodology, reported absolute SUVmax thresholds
are not simply valid for other institutions ().
Standardized optimized FDG-PET protocols are
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required for interinstitution comparison of study re-
sults and advancement of PET research (, ).
FDG-PET in thyroid nodules with Hu¨rthle
cell cytology
Multiple studies observed aberrant FDG-PET char-
acteristics in indeterminate nodules with Hu¨rthle cell
cytology: both benign and malignant lesions are
mostly FDG-positive. Twenty-nine Hu¨rthle cell lesions
were reported by Deandreis et al. (), consisting %
of their study population and providing an explana-
tion for their limited sensitivity. Moreover, Hu¨rthle
cell adenoma generally demonstrated a signiﬁcantly
higher SUVmax than other benign lesions (,
–, , ). The proportion of Hu¨rthle cell
cytology in individual studies is relatively small, but
overall FDG-PET seems inadequate in these
neoplasms.
Availability, cost-eﬀectiveness, and limitations
of FDG-PET
PET systems are less widely available than conven-
tional gamma cameras. Moreover, F used for
F-FDG synthesis is produced in cyclotrons, and
transport distances are limited due to the short half-life
of this isotope (~ minutes). In Europe, FDG-PET/
CT is ~. to  times more expensive than mTc-MIBI
SPECT/CT. The radiation exposure of FDG-PET/CT
is largely accounted for by the FDG dosage at ~mSv/
MBq, i.e., ~ to mSv for a typical activity of MBq
administered to an average adult (). Insights re-
garding common practice total-body FDG-PET/CT
imaging are changing (, ). The CT radiation
dose greatly varies, and can be less than . mSv for
a low-dose CT of the neck region only. When scanning
the thyroid region only, a longer imaging time can
compensate for a reduction in FDG dose, which would
lower the radiation burden as well as the costs. Such
solutions may counter prevailing reservations re-
garding ionizing radiation exposure. Additionally,
partial-body acquisition could limit the number of
coincidental PET-positive ﬁndings. Much of the
criticism on FDG-PET focuses on these potential
incidental ﬁndings, which require additional di-
agnostics, are not always clinically relevant and may
negatively impact potential cost-eﬀectiveness (,
). Malignant ipsi- or contralateral thyroid inci-
dentalomas are reported while the nodule under in-
vestigation was histopathologically benign (, ).
PET-positive incidentalomas are histopathologically
malignant in ~% of patients (). Cost-eﬀectiveness
of FDG-PET/CT was modeled by Vriens et al. ().
From a Dutch health care perspective, FDG-PET/CT
driven treatment would decrease the rate of unbe-
neﬁcial diagnostic hemithyroidectomies for benign
thyroid nodules by % and reduce the costs per
patient by V compared with the V, ex-
penses for conventional surgical treatment. Also,
FDG-PET/CT was favored over the miRInform® and
Aﬁrma® GEC ().
Contrasting the generally strong sensitivity, spec-
iﬁcity of FDG-PET is consistently poor. The un-
derlying mechanism is not yet fully elucidated. The
negative inﬂuence of Hu¨rthle cell cytology may be
partly responsible. It could also be explained by cel-
lular atypia, which was signiﬁcantly and independently
related to FDG uptake, and found in both benign and
malignant lesions. Atypia was also related to the
presence of Hu¨rthle cells (). Sebastianes et al. ()
hypothesized that FDG uptake is related to variations
in gene expression patterns. They suggested that ge-
netic variations between populations may also explain
the varying diagnostic accuracy of FDG-PET between
studies.
In conclusion, FDG-PET(/CT) has the potential to
accurately rule-out malignancy in all indeterminate
nodules except Hu¨rthle cell lesions. It could prevent
unnecessary diagnostic surgery for a substantial
number of benign thyroid nodules. Sample sizes of
existing studies are small, but larger prospective trials
are currently ongoing to settle the diagnostic value of
this technique and its utility in clinical practice. We
recommend that these studies also focus on identifying
(genetic) causes for the occasional false-negativity and
generally low speciﬁcity of this technique.
Diﬀusion-weighted magnetic resonance imaging
Diﬀusion-weighted magnetic resonance imaging
(DW-MRI) is a functional nuclear magnetic resonance
imaging technique that evaluates the rate of random
(Brownian) motion of water in tissue, also called
diﬀusivity. By applying diﬀusion-sensitizing magnetic
gradients (the strength and duration of which are
expressed as b-values) diﬀerent levels of diﬀusion-
weighting are obtained: from nondiﬀusion images
(b-value =  s/mm) to highly diﬀusion weighted
images (i.e., b-value.  s/mm) (). Lesions that
show high signal intensity on DW-MRI images with
a high b-value thus show restricted diﬀusion. The
apparent diﬀusion coeﬃcient (ADC; in mm/s) is
calculated based on the exponential relationship be-
tween signal intensity and the corresponding b-value
according to S(b) = S()*e2b*ADC. A high ADC rep-
resents a high degree of diﬀusion; a low ADC rep-
resents diﬀusion restriction (, ). DW-MRI thus
allows noninvasive quantiﬁcation of tissue properties
without ionizing radiation exposure for the patient.
Diﬀerentiation between benign and malignant tissues
by DW-MRI is based on the assumption that increased
cell proliferation, cellular-density, and disorganized
structures in malignant tissue restrict random motion
and thus diﬀusion of water: a lower ADC-value, to-
gether with high signal intensity at high b-values, is
more suspicious for malignancy (, ). Oppo-
sitely, increased ADC-values suggest free movement of
water molecules in the tissue. It is found in for example
176 de Koster et al Diagnostics in Indeterminate Thyroid Nodules Endocrine Reviews, April 2018, 39(2):154–191
REVIEW
Downloaded from https://academic.oup.com/edrv/article-abstract/39/2/154/4782710
by Radboud University user
on 12 June 2018
edema, colloid follicles, ﬁbrous tissue, hemorrhage,
and calciﬁcation, all of which associated with benign
tissues (). Prior application of DW-MRI in i.e.,
neuroradiology, breast, and lymph nodes showed high
diagnostic accuracy (, ).
Recent exploratory studies in small cohorts of
thyroid nodules found distinctively higher ADC
values for benign than malignant nodules (–,
–). A recent meta-analysis in  cytologically
unselected thyroid nodules estimated that DW-MRI
had % sensitivity and % speciﬁcity to distinguish
thyroid carcinoma (). Among the individual
studies, however, presented optimum ADC thresholds
varied and were not externally validated (–,
–).
Only one small study had assessed DW-MRI in
indeterminate thyroid nodules to date. Nakahira
et al. () reported a mean ADC value of . 6
. *2 mm/s in malignancies opposite . 6
. *2 mm/s in benign nodules with in-
determinate cytology. These results were similar to
those of their entire study population (n = ), in which
a cutoﬀ ADC value of . 6 . *2 mm/s was
% sensitive and % speciﬁc.
Availability and limitations of DW-MRI
DW-MRI is infrequently and only experimentally used
in the workup of thyroid nodules. Nonetheless, the
worldwide availability and application of MRI is
growing. As it uses no ionizing but only radio-
frequency radiation, the associated risk to the patients
is limited, provided that speciﬁc measures are taken for
patients with MRI-incompatible implanted devices or
metal. No MRI-contrast is necessary for DW-MRI,
thus avoiding gadolinium-associated toxicity. As the
spatial resolution of MRI-scanners is still improving,
technical limitations of DW-MRI with regard to
minimal lesion size are becoming less relevant com-
pared with SPECT and probably also PET. Still, spatial
resolution of DW-MRI sequences is less than that of
conventional anatomical MRI-sequences.
There are several major limitations to DW-MRI.
MRI is still a rather costly technique; additional se-
quences such as DW-MRI adds scanner time (~ to 
minutes) per patient and thus further increases costs.
DW-MRI methodology is not standardized yet and its
optimal settings still unsettled, leading to varying ADC
and b-values (, , ). Suboptimal methodology
or artifacts cause poor image quality, impede accurate
interpretation, and caused undesirable exclusions from
already small-sized studies, with reported exclusion
rates up to % (, , ). Image artifacts are
often caused by inhomogeneity in pathologic tissues or
by their vicinity to interfaces between soft-tissues and
bone or air, a source of MRI-artifacts speciﬁcally in the
thyroid region. Besides viable tumor tissue, malignant
tumors partly exist of components with high diﬀu-
sivity, such as necrosis, cystic components, or
intratumoral hemorrhage (, ). For accurate
ADC measurement, such macroscopic areas should be
manually avoided when drawing a region-of-interest.
However, avoiding microscopic areas of similar origin,
invisible to the human eye, is an impossible task ().
Furthermore, it is hypothesized that the substantial
amounts of follicular or Hu¨rthle cells limit the di-
agnostic accuracy of DW-MRI, speciﬁcally in in-
determinate thyroid neoplasms. Follicular and Hu¨rthle
cell neoplasms are known for their varying colloid
tissue involvement. Histologically they contain more
ﬂuid. Thus, DW-MRI would inaccurately provide
a more benign image (, ). These hypotheses are
currently based on very limited evidence. Further
prospective validation studies are desired to determine
the possible diagnostic value of DW-MRI in in-
determinate thyroid nodules. Future prospects also
include improvements of the technique, including
consensus on methodology and standardization of
acquisition techniques.
Combined and Multistep Diagnostics
The previous sections of this review addressed the
large number of available diagnostic tools to assess
indeterminate thyroid nodules. Most studies focused
on a single diagnostic technique only. The elimination
of between-study population-level diﬀerences is
a major advantage when comparing the performance
of multiple diagnostics independently in one study,
optimally in a prospective, independent, and blinded
fashion. Moreover, assessment of multiple techniques
in one study allows investigation of the comple-
mentary value of multiple techniques as a diagnostic
tool by means of simultaneous or sequential testing
while at the same time aiding to further unravel tumor
biology as a research tool, especially in the current
multidisciplinary in-hospital working environment.
For example, the question how the presence of
a certain oncogenic mutation relates to the (positive)
result of an FDG-PET scan could be addressed.
Piccardo et al. () compared mTc-MIBI, FDG-
PET/CT, and US plus USE in  indeterminate TIR
nodules with a % malignancy rate. FDG-PET/CT
was the superior technique with % sensitivity and
% speciﬁcity. Following a nonspeciﬁc positive FDG-
PET result, review of US characteristics oﬀered slight
further diﬀerentiation; it improved speciﬁcity to %.
However, an additional negative mTc-MIBI scan
increased speciﬁcity to %; this combination was
found in % of patients.
Giovanella et al. () performed both mTc-MIBI
and a seven-gene mutation panel in cold in-
determinate thyroid nodules. Combined testing did
not improve diagnostic accuracy. Performance of the
gene mutation panel was inferior to mTc-MIBI
imaging. Of the seven (%) mutation-positive
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nodules (four RASmutations and three PAX/PPARg
rearrangements), only four were malignant. It is un-
clear whether the low sensitivity of the gene mutation
panel in this study can be explained by the selected
population of hypofunctioning nodules.
Elastosonography and ultrasonography
USE is superior to US in indeterminate thyroid
nodules, both individual US characteristics as well as
combined US patterns described in various articles
(–, , , , ). Two recent prospective
studies demonstrated that additional USE evidently
improved the diagnostic accuracy of US. Garino et al.
() included nodule stiﬀness as additional char-
acteristic into a panel of US characteristics and
demonstrated that USE identiﬁed eight additional
malignancies that would have been missed by US
assessment alone. Presence of one or more suspicious
US/USE features was % sensitive; two or more %
sensitive and % speciﬁc. Benign test results were
found in % of patients. The authors suggested that
the .% remaining risk of malignancy, similar to the
benign cytology category, would justify follow-up
instead of diagnostic hemithyroidectomy in this
group (). In another study of  Thy nodules,
semiquantitative USE correctly diagnosed % of the
histopathologically benign lesions that were consid-
ered suspicious for malignancy on US, and % of the
malignancies that were misdiagnosed as benign on US
(). These results suggest that the existing TIRADS
classiﬁcation could be extended with tissue elasticity
features. In unselected thyroid nodules, this improved
TIRADS sensitivity, but not speciﬁcity (, ). The
combination is a suitable topic for future research in
indeterminate thyroid nodules. Major beneﬁt is that
the two techniques are individually inexpensive and
obviously easily combined during one diagnostic
procedure. Cost-eﬀectiveness can be anticipated.
US and mutation analysis
US assessment was also reported in various studies on
gene mutation analysis, presumably because US data
were usually readily available in clinical studies at no
additional costs and thus easily combined with results
of more experimental techniques. Even though US
assessment improved the diagnostic accuracy of both
FDG-PET and elastosonography, combined use of US
with the sensitive Aﬁrma® GEC or speciﬁc BRAF
mutation analysis demonstrated little additional di-
agnostic value (). Suspicious US features such as
hypoechogenicity, presence of calciﬁcations, and
hypervascularity were not predictors of malignancy in
Aﬁrma® GEC-positive nodules (). Also, as expected
by their individual association to classic PTC, a posi-
tive BRAFVE mutation was correlated to the
presence of suspicious US features in unselected
nodules, including hypoechogeneity and the presence
of microcalciﬁcations (, , ). BRAF mutation less
frequently occurred in thyroid nodules without sus-
picious US features (, ). In Bethesda III and IV
thyroid without suspicious US features, the prevalence
of the BRAF mutation was only .% (/) in the
study by Seo et al. (), very low, particularly for
a South Korean population, all while the malignancy
rate was still % (/). Considering the negligible
yield at additional costs, BRAF mutation analysis
might not be contributory in indeterminate nodules
without suspicious US features. An even lower yield
from BRAF mutation analysis in US-unsuspicious
nodules is presumed in populations with a lower
general prevalence of BRAF mutations. Additionally,
these results suggest a diﬀerent US appearance of
BRAF mutation-negative malignancies, or a diﬀerent
molecular proﬁle of thyroid carcinoma without sus-
picious US features.
RAS mutation analysis and assessment of the
typical suspicious US features could be complemen-
tary in the diﬀerentiation of indeterminate thyroid
nodules, as follicular-type thyroid carcinomas are
associated with RAS mutations and infrequently
showed the typically suspicious US features (, ,
–). Combined assessment could improve di-
agnostic accuracy of either technique in indeterminate
thyroid nodules, identifying papillary thyroid malig-
nancies through classic suspicious US features and
follicular-type carcinoma by RAS mutation analysis.
However, challenges for clinical practice continue to
exist in the imperfect speciﬁcity of RAS mutation
analysis, and the interobserver variability and ambi-
guity of certain US features.
ICC and mutation analysis
In histopathology samples, certain genetic alterations
were correlated to positive staining for speciﬁc
immunomarkers: PAX/PPARg rearrangement was
associated with galectin- reactivity, and RAS point
mutation with HBME- (). Only one study inves-
tigated this combination of techniques in indeterminate
thyroid cytology. Although no significant correlation
was demonstrated between positive BRAFVE muta-
tion and galectin- overexpression, beneﬁtting possible
complementary use, no additional diagnostic value was
demonstrated either ().
MicroRNA and mutation analysis
Combined microRNA expression proﬁling and mu-
tation analysis could accurately aid diagnosis and
prognosis of thyroid malignancy. Distinct microRNAs
have been related to oncogenic mutations. For ex-
ample, miR-, miR-, and miR-b were more
overexpressed in BRAF- and RAS-mutated PTC. High
expression of miR- was associated with RET/PTC
rearrangement (, ). The ﬁrst step toward di-
agnostic integration of the two techniques was taken
by Laborier et al. (), who tested the com-
mercially developed -microRNA thyroid classiﬁer
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ThyraMIR simultaneously with the miRInform®
thyroid. The ThyraMIR was designed to increase the
sensitivity of the miRInform® without aﬀecting its
speciﬁcity. Combined use demonstrated % sensi-
tivity and % speciﬁcity (). A recent decision an-
alytics model for Bethesda III and IV nodules
estimated that combined miRInform® and
ThyraMIR testing was cost-eﬀective, reducing the
rate of unnecessary surgery (diagnostic hemi-
thyroidectomy as well as two-step thyroidectomies)
from % to % and saving $ per patient in the
ﬁrst year of treatment or $ per avoided surgery.
However, it is not described how the economic
consequences of the % missed malignancies are
accounted for in this model (). The economic as well
as medical–ethical consequences of such a high
number of missed malignancies question the current
clinical utility of this combination of expensive
techniques.
In brief, the combined or sequential use of multiple
diagnostics in indeterminate thyroid nodules was
infrequently studied. Regrettably, the available studies
also mostly remained within their own ﬁeld of ex-
pertise: comparing tests either within the domain of
pathological (molecular) techniques or within the
domain of imaging. Although a sequential combina-
tion of a sensitive and an uncorrelated speciﬁc test
might bring the solution that this clinical issue has
been waiting for, the most accurate combination of
tests cannot reliably be determined yet.
Recent Developments and Future Prospects
The cancer genome atlas
Papillary thyroid cancer was one of the cancers tar-
geted by the cancer genome atlas (TCGA) research
network, a large collaborative project by the National
Cancer Institute and National Human Genome Re-
search Institute. The incentive of the project is to map
genomic alterations occurring in  types of cancer in
, patients and improve the understanding,
classiﬁcation, and extending possibilities for targeted
therapy of these cancers (). Genetic alterations of
all kinds were detected in nearly  clinically non-
aggressive PTCs (classical, follicular, and tall cell
variants) using one proteomic and six genomic plat-
forms. PTC harbored fewer somatic mutations than
other human cancer types, but if they were present,
driver mutations were detected in the majority of the
cancer cells. As expected, the known driver mutations
in the MAPK/ERK pathway were dominant, con-
ﬁrming the mutually exclusive relation for BRAF and
RAS point mutations and RET/PTC rearrangements.
Other detected genetic alterations included genetic
variations of the TERT promoter, PIK and PPARg
pathways, as well as new alterations of known and new
drivers, such as EIFAX, PPMD, and CHEK.
Moreover, molecular subtypes of, for example, BRAF-
mutated PTC were identiﬁed and linked to diﬀerent
clinical subtypes. The role of microRNA in de-
termining cancer phenotype was elaborated, allowing
better understanding of clinical behavior of various
genetic variants of PTC. Somatic copy number al-
terations were mostly linked to FVPTC. Ultimately,
the TCGA Research Network envisions a reclassiﬁca-
tion of thyroid carcinoma, abandoning the discrimi-
nation between PTC and FTC, and classifying
according to molecular subtypes instead of by histo-
pathological subtype ﬁrst (). The identiﬁed markers
may not just have an application in the diagnosis of
thyroid carcinoma, but also in better risk-stratiﬁcation
of the diﬀerent cancers and in targeted therapies. The
plurality of applications is best known for the
BRAFVE mutation, which has an association with
clinically more aggressive tumor behavior on several
fronts. Also, nonthyroid malignancies carrying a BRAF
mutation are now (experimentally) treated with RAF
inhibitors (, ).
There is little doubt that molecular classiﬁcation
systems are the future of oncology diagnostics in all
types of human cancers. The position of histopatho-
logical assessment is changing, but cannot be re-
nounced. With the current knowledge of thyroid
genomics, the need to distinguish the mutated ma-
lignant from the mutated benign, premalignant,
neoplasms remains, with all due consequences for the
surgical and postoperative treatment strategy.
Cytological application of the TCGA set was also
already investigated in a recent study. Pagan et al. ()
validated a panel containing the genomic alterations
identiﬁed by the TCGA in  FNAC samples selected
from a previous cohort study, including  in-
determinate thyroid nodules (, ). In the latter,
% sensitivity and % speciﬁcity were demonstrated.
In the same set of patients, Pagan et al. () also
performed the Aﬁrma® GEC. The GEC yielded less
false-negatives and a much higher sensitivity. Even
though technical limitations of the applied sequencing
techniques could leave RNA transcriptions with low
expression levels undetected and thus negatively in-
ﬂuence sensitivity of the TCGA set, the scopes of the
TCGA and GEC most likely explain their diﬀerence in
performance. The TCGA was developed using PTC
only. It did not include follicular lesions and their
distinctive genetic alterations. Moreover, in contrast to
the GEC, the TCGA set was not optimized for pre-
operative diagnostic application in indeterminate
thyroid nodules (). Consequently, the comparison
performed by this Veracyte-sponsored study seems
unjust: it is obvious that the Aﬁrma® GEC yielded
better diagnostic performance in this speciﬁc clinical
setting. Yet, the results of this study did prove that
a large panel of genetic alterations such as the TCGA
was not useful in clinical practice without further
expansion of the scope of the panel toward follicular
“There is little doubt that
molecular classiﬁcation
systems are the future of
oncology diagnostics in all
types of human cancers.”
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thyroid neoplasms. Still, the genetic alterations and
their relations detected by TCGA are groundbreaking
for the progression of research. From these compre-
hensive sets of biomarkers, we may select new com-
binations of genetic alterations for future clinical
research to develop an accurate rule-in or rule-out
molecular test for indeterminate thyroid nodules.
Proteomics
Other molecular advances include protein expression
diagnostics, or proteomic proﬁling. These techniques
allow for more detailed insight in the molecular bi-
ology and protein expression of thyroid neo-
plasms. For example, matrix-assisted laser desorption
ionization/mass spectrometry imaging is able to si-
multaneously visualize the spatial distribution of
proteins and proﬁle up- and downregulated protein
expression in relation to the morphological features of
the thyroid specimen. These and related proteomic
techniques could identify new biomarkers for pre-
operative cytological diagnosis, but require high levels
of expertise. Application to thyroid cytology has so far
been investigated by few studies (, ). Ex-vivo
cytology studies show accurate and reproducible dif-
ferentiation between various lesions, including the
currently diﬃcult to diagnose Hu¨rthle cell neoplasms
(). No studies investigated the diagnostic value of
proteomics in in-vivo indeterminate thyroid cytology
yet.
Discussion
This review provides a comprehensive overview of the
available literature on molecular and imaging bio-
markers as additional diagnostics for thyroid nodules
with indeterminate cytology (Bethesda III and IV) and
their application in a clinical preoperative setting.
Clinical utility requires more from a diagnostic than
mere well-validated test performance and high rule-in
or rule-out capacity. The  ATA guidelines sug-
gested that the ideal rule-out diagnostic for thyroid
carcinoma should have an NPV similar to a benign
cytological diagnosis (~.%) and the ideal rule-in test
a PPV that is at least similar to a malignant cytological
diagnosis (~.%) (, ). The balance between test
sensitivity and speciﬁcity, and their prevalence-
dependent derivatives PPV and NPV, directly re-
ﬂects on feasibility and cost-eﬀectiveness estimates. A
diagnostic with (near) perfect sensitivity but limited
speciﬁcity is ineﬃcient and unlikely cost-eﬀective: the
NPV will be close to %, but the majority of nodules
will test positive. Therefore, instead of focusing on the
reproducible highest sensitivity or speciﬁcity, a di-
agnostic is better appreciated by end points such as
desired minimal rates of accurately prevented unbe-
neﬁcial surgeries or accurately diagnosed carcinomas.
More importantly, clinical utility demands that
implementation of the ancillary test leads to changes in
patient management and overall health beneﬁts ().
All these requirements directly depend on a plurality
of epidemiological and economic factors within the
tested population, such as the local test availability,
professional expertise, and case mix—prevalence of
malignancy as well as the balance of various sub-
types of indeterminate cytology including especially
Hu¨rthle-cell neoplasms and BRAF-mutation. Addi-
tionally, clinical utility considerations should include
less tangible factors such as physician and patient
preference, multidisciplinary decision-making, and
compatibility with everyday clinical routine and lo-
gistics in endocrine practice. All things considered,
global perspectives regarding the preferred diagnostic
for indeterminate thyroid nodules likely greatly diﬀer.
Recommendation for clinical use of rule-out tests
The most accurate currently available rule-out tests are
the Aﬁrma® GEC and FDG-PET(/CT) imaging. The
Aﬁrma® GEC had strikingly high sensitivity in nearly
all studies (, , , –). However, there are
concerns regarding the lack of strong validation
studies. With a high degree of missing histology, es-
pecially in GEC negative nodules, there is a potentially
strong diminution of the tests’ sensitivity if unresected
GEC-negative lesions were less often benign than
presumed. In the United States, physicians should
locally validate the tests’ utility prior to implementa-
tion. However, with its limited global availability, high
costs and low probability of cost-eﬀectiveness, clinical
implementation of the Aﬁrma® GEC outside the
United States is currently not favored (, , –).
FDG-PET/CT may be the preferred rule-out test
for indeterminate thyroid nodules in a European
setting. With suﬃcient validation studies with com-
plete histopathological follow-up, it demonstrated
consistent high sensitivity and a benign test result in
% of the patients, although the number of currently
published patients is moderate. Cost-eﬀectiveness of
FDG-PET over other diagnostics is presumed (). Its
popularity in the United States is more limited, al-
though the eﬃcacy of this molecular imaging tech-
nique could likely compete with molecular biomarkers
panels, even if the costs per scan are somewhat higher
than in Europe. The main drawback of FDG-PET/CT
is its, admitted minor, risk to the patient by using
a limited dose of ionizing radiation.
The recently announced version  of the Thyro-
Seq® may become a prime contender. Dependent on
the case mix, the ThyroSeq® v. anticipated high
negative predictive value (). However, the number of
studies to conﬁrm test performance and clinical utility
in diﬀerent patient populations is limited. Clinical
results for the ThyroSeq® v are eagerly awaited.
Semiquantitative elastosonography could be
a suitable alternative, in particular in case a more
economic test is required. However, overﬁtting and
180 de Koster et al Diagnostics in Indeterminate Thyroid Nodules Endocrine Reviews, April 2018, 39(2):154–191
REVIEW
Downloaded from https://academic.oup.com/edrv/article-abstract/39/2/154/4782710
by Radboud University user
on 12 June 2018
lack of external cut-oﬀ validation likely overestimated the
performance of this technique in the limited number of
available studies. If future prospective studies can conﬁrm
its performance and thresholds of this operator-
dependent but globally accessible method, USE could
become a more important diagnostic in this ﬁeld.
None of the diagnostic techniques under in-
vestigation in this review has a perfect NPV or fulﬁlls
the threshold proposed by the ATA. A number of
malignant nodules will be misdiagnosed as benign on
ﬁrst assessment. Considering the typical indolent
clinical course of diﬀerentiated thyroid cancer, follow-
up of these initially false-negative nodules will most
likely still result in timely diagnosis without relevant
treatment delay and dismal prognostic consequences.
Recommendation for clinical use of rule-in tests
The best rule-in performance was unmistakably
demonstrated by BRAF mutation analysis, which
showed perfect % speciﬁcity in an abundance of
studies. Yet, strong regional diﬀerences in prevalence
of BRAFmutations have a major impact on its clinical
utility, especially when comparing South Korea to
other countries. Moreover, the analysis most likely has
very low yield in Bethesda IV nodules, in which the
mostly follicular type malignancies are more fre-
quently RAS-mutated (, , , ). Testing
for individual genetic alterations other than the
BRAFVE point mutation is not useful. In American
and European settings, a gene mutation panel is likely
preferred over any individual mutation analysis.
Promising rule-in capacity was also demonstrated for
Galectin- ICC, an infrequently applied technique with
limited validation studies. Further prospective studies are
warranted to validate its performance in indeterminate
thyroid nodules and endorse its possible clinical use.
Besides BRAF mutation analysis, none of di-
agnostics meet the  ATA requirements of an ideal
rule-in test. Compared with ruling-out tests, ruling-in
tests face an additional challenge. With a generally low
frequency of thyroid carcinoma in indeterminate
thyroid nodules, achieving a reliable PPV (higher than
%) can be a major challenge despite adequate test
speciﬁcity. Such high demands to a ruling-in test
advocate the use of a ruling-out test in populations
with a limited pretest probability of malignancy.
Clinical recommendation for a step-wise approach
Most of the diagnostic modalities are optimized for
either ruling in or ruling out malignancy.
No single diagnostic addressed in the current re-
view currently has it all: both a near-perfect sensitivity
and a near-perfect speciﬁcity, and (proven) cost-
eﬀectiveness. It is extremely challenging to develop
such test performance parameters in a single di-
agnostic. Even promising new diagnostics, such as the
ThyroSeq® and ThyraMir, require substantial fur-
ther optimization to get near this diagnostic utopia.
With the diagnostics currently available in the
clinical setting, a multimodality stepwise approach
could oﬀer a conclusive diagnosis for indeterminate
thyroid nodules, sequentially combining one sensitive
rule-out and one speciﬁc rule-in test. Unfortunately,
thus far few studies investigated this approach (, ).
Combinations of (molecular) imaging and somatic
genetics were especially scarce. There is currently
insuﬃcient evidence to accommodate reliable in-
terpretation of sequentially used tests, as performance
of the second test is unknown in a population pre-
selected by the ﬁrst. Besides choosing two accurate and
uncorrelated tests to achieve maximum diagnostic
accuracy, the sequence of testing, local availability, and
costs of the selected diagnostics are crucial. Costs of
two or more additional tests may compromise cost-
utility estimates. Available cost-eﬀectiveness studies
for individual diagnostic modalities were additionally
greatly susceptible to global variations in population-
dependent factors such as pretest probability of thy-
roid carcinoma and local test performance, and
varying health care costs including the surgical re-
imbursement rates (, , , ). Reported surgical
and hospitalization costs range from $ to $
for hemithyroidectomy, $ to $ for comple-
tion thyroidectomy, and $ to $, for initial
total thyroidectomy. Secondary expenses following
surgery should be considered as well, including
postoperative observation, thyroid hormone replace-
ment (approximately $ per patient per year),
treatment of hypoparathyroidism (approximately $
per patient per year), and resolution of rare but po-
tentially serious surgical complications (, , ,
). Secondary end points such as quality of life and
survival are of minor importance to cost-eﬀectiveness,
due to the generally indolent course of diﬀerentiated
thyroid cancer, adequate treatment options, and
overall low disease-related mortality (, , ).
Recent discussions in thyroid histopathology
Histopathology is classically based on microscopic
assessment of tumor phenotype, aided by IHC.
However, this “gold standard test” is also subject to
advancing insights regarding tumor phenotype, in-
creasingly aided by knowledge regarding tumor ge-
notype. Mutation-negative malignancies resulting
from indeterminate cytology were frequently identi-
ﬁed as encapsulated follicular variants of papillary
thyroid carcinoma without histologic features of ag-
gressive behavior (, , , , ). Also, several
studies deﬁned a separate intermediate histopatho-
logical category called “(follicular) tumor of uncertain
malignant potential” for encapsulated, well-diﬀerentiated
follicular tumors with questionable PTC-type nuclear
changes (, , , ). These examples illustrate
one of the important ongoing discussions in thyroid
histopathology. In , Nikiforov et al. () pro-
posed an oﬃcial downscaling of the classiﬁcation of
“Histopathology is classically
based on microscopic
assessment of tumor
phenotype, aided by IHC.”
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proven noninvasive encapsulated FVPTCs, renaming
them “noninvasive follicular neoplasm with papillary-
like nuclear features” (NIFTP). The behavior of these
neoplasms is benign unlike other thyroid carcinoma
subtypes, showing no evidence of recurrent disease
after a median -year follow-up. Approximately one
in four of the neoplasms in the retrospective cohort
were mutated, most frequently carrying RAS (NRAS)
or PAX/PPARg alterations. Presence of a mutation
likely predisposes the NIFTP to progress into an in-
vasive encapsulated FVPTC, justifying surgical re-
section. Treatment of NIFTP should most likely be
limited to hemithyroidectomy, waiving totalizing
thyroidectomy, and radioiodine ablation (). Al-
though revolutionizing, this new nomenclature
complicates mutation-based preoperative decision-
making (, , ). The justiﬁcation to skip two-
stage surgery and perform a total thyroidectomy at
once for mutation-positive nodules is the driving force
of the seven-gene mutation panel and similar tests, but
would be overkill for the subgroup of NIFTP ().
Nonetheless, most of the undesirable possible over-
treatment for NIFTP is likely resolved if RAS-mutated
indeterminate nodules are treated with hemi- instead of
total thyroidectomy, as previously suggested. No com-
prehensive diagnostic test is currently available to di-
agnose mutation-positive NIFTP preoperatively, as
follicular tumor invasiveness and encapsulation cannot
be distinguished on cytology.
Hu¨rthle cell cytology
The Achilles heel of many diagnostics investigated in
this review is cytology suspicious for a Hu¨rthle cell
neoplasm (Bethesda IV SHCN/HCN). Hu¨rthle cells
are oxyphilic cells with abundant cytoplasm and an
enlarged nucleus with a prominent nucleolus. They are
found in benign thyroid diseases such as Hashimoto’s
thyroiditis, but also occur in the notorious Hu¨rthle cell
adenoma and carcinoma, the oncocytic variant of FA
and carcinoma (, ). Although Hu¨rthle cell car-
cinomas (FTC-OV) are rare, their aberrant clinical
course and association with invasive features justiﬁes
the special attention given to Hu¨rthle cell cytology by
the Bethesda and other classiﬁcation systems. An
accurate additional diagnostic is desired. Disap-
pointingly, several studies concluded that the in-
vestigated test was accurate in all except Hu¨rthle cell
lesions (, , , ). ICC handed some solutions,
although promising results of combined galectin- and
CK- staining have not yet been validated ().
Besides that, BRAF, RAS, RET/PTC, or PAX/PPARg
alterations are only occasionally found (, ). These
ﬁndings support previous presumptions that oncocytic
thyroid nodules are a completely separate entity with
a unique molecular and phenotypic proﬁle (–).
Malignant transition in Hu¨rthle cell nodules most
likely involves the PIKCA-Akt-mTOR and Wnt/
be`ta-catenin pathways rather than the MAPK/ERK
pathway (, ). Rare TP mutations, usually
associated with poorly diﬀerentiated and anaplastic
carcinoma, were recently also identiﬁed in well-
diﬀerentiated Hu¨rthle cell nodules (). Also, re-
current FTC-OV have shown genome haploidisation,
a rare phenomenon in other types of diﬀerentiated
thyroid carcinoma (). Speciﬁc markers for the pre-
operative molecular diﬀerentiation of Hu¨rthle cell
nodules should be developed. Adaptation of existing tests
to additionally suit Hu¨rthle cell nodules (e.g., the Aﬁrma®
GEC) is a strategy being explored, for example, by the
ThyroSeq® v and the Aﬁrma® Gene Sequence Classiﬁer.
Caution should be taken that these adaptations do not
decrease the diagnostic accuracy for nononcocytic le-
sions. MicroRNA expression proﬁling of these lesions is
currently also under investigation (, ).
Strengths and limitations of the current review
There are several important strengths and limitations to
this comprehensive review. This review provides
a complete overview of the available additional di-
agnostics for indeterminate thyroid nodules, resulting
from a careful and systematic literature selection and
quality appraisal. Diﬀerent types of clinical data of
various levels of evidence were considerately presented.
Nonetheless, this review is generally prone to inac-
curacies from low study quality, study heterogeneity,
and diﬀerent types of bias. For some of the assessed
diagnostics, the limited number of available publica-
tions and small study cohorts contribute to heteroge-
neity of data and loss of applicability. This mainly
concerns studies on nonroutine imaging techniques. By
nature, these clinical studies need to prospectively in-
clude subjects to voluntarily undergo an extra in-
vestigation with, at least in the clinical validation phase,
no implications for individual patient management.
These types of studies require more resources than
“further use” tissue biobank studies. Consequently, the
number of studies is more limited and published series
often are small. In contrast, cytological biomarker re-
search gratefully proﬁts from available large tissue
biobanks for initial validation studies. We believe
consistent results from properly designed imaging
studies should not be disregarded due to mere their
sample size, but be appreciated by the quality of their
study design and statistics.
Population-level study diﬀerences were often ob-
served, not only related to test performance but also
strongly varying malignancy rates that were often-
times much lower or higher than expected from
indeterminate thyroid nodules. Besides insupera-
ble epidemiological variations, the selection of in-
determinate cytology, and the retrospective nature of
many studies may have contributed to these
discrepancies.
The type of indeterminate cytology included by
individual studies varied, likely leading to between-
study heterogeneity. Besides global variations and
182 de Koster et al Diagnostics in Indeterminate Thyroid Nodules Endocrine Reviews, April 2018, 39(2):154–191
REVIEW
Downloaded from https://academic.oup.com/edrv/article-abstract/39/2/154/4782710
by Radboud University user
on 12 June 2018
known intra- and interobserver discordance, diverse
deﬁnitions of indeterminate cytology were adhered ().
Nowadays, the Bethesda system diﬀerentiates in-
determinate from benign and suspicious cytology in
a more standardized manner in both literature and
clinic. Bethesda III and/or IV and similar categories
from other classiﬁcation systems were frequently ap-
plied. Unfortunately, some studies also included small
numbers of Bethesda V nodules without presenting
results for individual categories separately (). Many
other studies adhered to their own deﬁnition of in-
determinate cytology. This especially, but not exclusively,
concerns studies published before the introduction of the
Bethesda system in .
Retrospective study designs and subsequent se-
lection bias—only including indeterminate thyroid
nodules that had undergone both thyroid surgery and
(routine) preoperative testing—likely also caused
overestimation of the true eﬃcacy of certain tech-
niques (e.g., BRAF mutation analysis or US).
Conclusion and Recommendations
In current-day practice, there are numerous additional
diagnostics available to further assess thyroid nodules
with indeterminate cytology, all with advantages and
disadvantages. This review provided a comprehensive
overview of the available literature on these tech-
niques, addressing both molecular and imaging
biomarkers, aiming to provide an objective and
nuanced comparison of their performance and cost-
eﬀectiveness with regard to rightful surgical decision-
making. Many of these diagnostics have either an
adequate rule-in or rule-out capacity, but no single
currently available test seems to serve both purposes
well. Diagnostics from the diﬀerent research ﬁelds
likely complement each other in a multimodality
stepwise diagnostic approach toward. Notwith-
standing, test performance is always population-
dependent. To correctly interpret the results, the
prevalence of malignancy and the performance, costs,
and feasibility of the desired diagnostic in the local
patient population should be known beforehand.
Local implementation studies are strongly recom-
mended to conﬁrm clinical utility. Most importantly,
the local decision favoring or opposing a certain
diagnostic should be a deliberate and multi-
disciplinary one. Cooperation between clinical en-
docrinologists, endocrine surgeons, pathologists,
radiologists, and nuclear medicine physicians is
crucial.
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